MASP-2 inhibitor and method of use

Abstract

This invention provides a small molecule synthesis inhibitor of mannan-binding lectin-related serine protease 2 (MASP-2) that is more selective for MASP-2 than for thrombin, a composition thereof, and a method for producing and using the same. [Solution] A pharmaceutical composition is provided comprising a compound having a specific structure or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient, which is useful in the treatment of MASP-2 related diseases and disorders, and in the manufacture of pharmaceuticals for treating MASP-2 related diseases and disorders.

Claims

1. Small molecule compounds exhibiting MASP-2 inhibitory activity for therapeutic use in the treatment of MASP-2-related diseases or disorders, wherein the following interactions (a) to (e): (a) Binding to one or more of the following in MASP-2 via H bonds: PRO 606, ASP 627, SER 628, ARG 630, SER 633, SER 654, GLY 656, SER 657, CYS 660, and GLN 665; (b) Bonding to one or more of ASP 627 and ARG 630 in MASP-2 by ionic interaction, electrostatic interaction, or hydrogen bonding; (c) Water molecules in MASP-2 interact with one or more of the following in MASP-2: TYR 602, TYR 607, ASP 627, SER 628, SER 657, ASN 659, GLU 662, TRP 655, GLY 656, CYS 660, GLN 665, TYR 666, VAL 668, and ARG 630; (d) Interacting with one or more of PHE 529, TYR 607, and TRP 655 in MASP-2 via π-π interactions; and (e) Interacting with one or more of the following in MASP-2 via van der Waals contact: ALA 468, ALA 469, HIS 483, ASP 526, ALA 527, GLY 528, PHE 529, LEU 575, PRO 606, TYR 607, PRO 608, SER 611, ASP 627, SER 628, CYS 629, ARG 630, GLY 631, ASP 632, SER 633, GLY 634, GLY 635, VAL 653, SER 654, TRP 655, GLY 656, SER 657, MET 658, ASN 659, CYS 660, GLN 665, GLY 667, and TYR 669 Show one or more of the following: It is not an endogenous MASP-2 ligand. compound.

2. Small molecule compounds exhibiting MASP-2 inhibitory activity for therapeutic use in the treatment of MASP-2-related diseases or disorders, wherein the following interactions (a) to (e): (a) Binding to one or more of ASP 627, SER 628, SER 654, GLY 656, GLN 665, and SER 657 in MASP-2 via H bonds; (b) Bonded to ASP 627 in MASP-2 by ionic interaction, electrostatic interaction, or hydrogen bonding; (c) Water molecules in MASP-2 interact with one or more of the following in MASP-2: ASP 627, GLN 665, SER 657, ASN 659, SER 628, GLU 662, VAL 668, TYR 607, TYR 602, and ARG 630; (d) Interacting with one or more of PHE 529, TYR 607, and TRP 655 in MASP-2 via π-π interactions; and (e) Interacting with one or more of the following in MASP-2 via van der Waals contact: HIS 483, PHE 529, PRO 606, TYR 607, PRO 608, SER 611, ASP 627, SER 628, CYS 629, ARG 630, SER 633, VAL 653, SER 654, TRP 655, GLY 656, SER 657, MET 658, ASN 659, CYS 660, GLN 665, GLY 667, and TYR 669 Show one or more of the following: It is not an endogenous MASP-2 ligand. compound.

3. A compound according to claim 1 or 2, exhibiting one, two, three, four, or five of the interactions (a) to (e).

4. The compound according to any one of claims 1 to 3, wherein it is bonded by an H bond to one or more of PRO 606, ASP 627, SER 628, SER 633, SER 654, GLY 656, SER 657, CYS 660, and GLN 665 in MASP-2.

5. The compound according to any one of claims 1 to 4, which is bonded by an H bond to one or more of ASP 627, SER 628, SER 654, GLY 656, GLN 665, and SER 657 in MASP-2.

6. A compound according to any one of claims 1 to 5, which is bonded by 1 to 10 H bonds.

7. The compound according to any one of claims 1 to 6, wherein the compound is bonded to SER 654 and GLY 656 by three H bonds, and two H bonds to GLY 656 are present in MASP-2.

8. A compound according to any one of claims 1 to 7, which is bonded to one or both of ASP 627 and ARG 630 in MASP-2 by ionic interaction, electrostatic interaction, or hydrogen bonding.

9. A compound according to any one of claims 1 to 8, which is bonded to ASP 627 in MASP-2 by ionic interaction, electrostatic interaction, or hydrogen bonding.

10. A compound according to any one of claims 1 to 7, which does not bind to ASP 627 and ARG 630 in MASP-2 by ionic interaction.

11. A compound according to any one of claims 1 to 7, which does not bind to ASP 627 in MASP-2 by ionic interaction.

12. The compound according to any one of claims 1 to 11, wherein a water molecule in MASP-2 binds to one or more of TYR 602, TYR 607, ASP 627, SER 628, SER 657, ASN 659, GLU 662, TRP 655, GLY 656, CYS 660, GLN 665, TYR 666, VAL 668, and ARG 630 in MASP-2.

13. The compound according to any one of claims 1 to 12, wherein a water molecule in MASP-2 binds to one or more of ASP 627, GLN 665, SER 657, ASN 659, SER 628, GLU 662, VAL 668, TYR 607, TYR 602, and ARG 630.

14. The compound according to any one of claims 1 to 13, which is bonded by 1 to 20 water molecules in MASP-2.

15. The compound according to any one of claims 1 to 14, which is bonded by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 water molecules in MASP-2.

16. A compound according to any one of claims 1 to 15, which interacts with one or more of PHE 529, TYR 607, and TRP 655 in MASP-2 by π-π interactions.

17. A compound according to any one of claims 1 to 16, which interacts with one or more of ALA 468, ALA 469, HIS 483, ASP 526, ALA 527, GLY 528, PHE 529, LEU 575, PRO 606, TYR 607, PRO 608, SER 611, ASP 627, SER 628, CYS 629, ARG 630, GLY 631, ASP 632, SER 633, GLY 634, GLY 635, VAL 653, SER 654, TRP 655, GLY 656, SER 657, MET 658, ASN 659, CYS 660, GLN 665, GLY 667, and TYR 669 in MASP-2 by van der Waals contact.

18. A compound according to any one of claims 1 to 17, which interacts with one or more of HIS 483, PHE 529, PRO 606, TYR 607, PRO 608, SER 611, ASP 627, SER 628, CYS 629, ARG 630, SER 633, VAL 653, SER 654, TRP 655, GLY 656, SER 657, MET 658, ASN 659, CYS 660, GLN 665, GLY 667, and TYR 669 in MASP-2 by van der Waals contact.

19. Formula (VIII): A compound according to any one of claims 1 to 18, having the following characteristics.

20. M 1 The compound according to claim 19, wherein the compound is a member selected from the group consisting of the following: In the formula, each R 1 C 1 ~C 6 Alkyl, hydroxyl, C 1 ~C 6 Alkoxy, amino, C 1 ~C 6 A member independently selected from the group consisting of alkylamino and halo; Each n is an independently selected integer between 0 and 4; R 7 is a member selected from the group consisting of hydrogen, hydroxyl, and C 1 to C 6 alkyl; R 8 is hydrogen and C 1 ~C 6 It is a member selected from the group consisting of alkyl groups.

21. M 5 The compound according to claim 19 or 20, wherein the compound has the following formula: In the formula, R 5 C 3 ~C 7 Cycloalkyl, C 4 ~C 8 Cycloalkylalkyl, heteroaryl, and C 7 ~C 12 Arylalkyl or heteroarylalkyl (0-3 R 13 A member selected from the group consisting of (having substituents); or alternatively, R 5 and R 6 Together, they form 0 to 3 R 13 Forming a heterocycle with substituents; R 6 is hydrogen, C 1 ~C 6 Alkyl, C 3 ~C 7 Cycloalkyl, carboxy(C 1 ~C 6 Alkyl), C 7 ~C 12 Arylalkyl or heteroarylalkyl (0-3 R 13 (Having substituents), amino(C 1 ~C 8 Alkyl, and amide (C 1 ~C 8 A member selected from the group consisting of alkyls; or alternatively, R 6 and R 5 Together, they form 0 to 3 R 13 It forms a heterocycle with substituents.

22. Formula (VIIIA): A compound according to any one of claims 1 to 21, having the following characteristics.

23. A compound according to any one of claims 1 to 22, having a molecular weight of approximately 300 g / mol to approximately 600 g / mol.

24. A compound according to any one of claims 1 to 23, wherein the Ki for MASP-2 is lower than that for thrombin.

25. A pharmaceutical composition comprising a compound according to any one of claims 1 to 24 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

26. Small molecule compounds for use in the treatment of MASP-2 related diseases or disorders, (a) S1 pharmacophore group containing CA1 and N1 pharmacophore elements or CA1 and C5 pharmacophore elements; (b) S2 pharmacophore group containing H4 and O2 pharmacophore elements; and (c) S3 pharmacophore group containing a C2 pharmacophore element and an N2 or H3 pharmacophore element Includes combinations of pharmacophore elements, C2 and C5 are hydrophobic groups; CA1 is an aromatic ring; H3 and H4 are hydrogen bond donors; N1 and N2 are cationic groups; O2 is a hydrogen bond acceptor; Compounds in which C2, C5, CA1, H3, H4, N1, N2, and O2 are located within the coordinate ranges shown in Table 3.

27. The compound according to claim 26, wherein C2, C5, CA1, H3, H4, N1, N2, and O2 are coordinates within the ranges shown in Table 4.

28. The compound according to claim 26 or 27, wherein C2, C5, CA1, H3, H4, N1, N2, and O2 are coordinates within the ranges shown in Table 5.

29. The compound according to any one of claims 26 to 28, wherein the S1 pharmacophore group comprises CA1 and N1 pharmacophore elements.

30. The compound according to claim 29, wherein the S1 pharmacophore group further comprises a C3 pharmacophore element, and the C3 is a hydrophobic group with coordinates within the range shown in Table 6.

31. The compound according to claim 30, wherein C3 represents a coordinate within the range shown in Table 7.

32. The compound according to claim 31, wherein C3 represents a coordinate within the range shown in Table 8.

33. The compound according to any one of claims 26 to 32, wherein the S1 pharmacophore group comprises CA1 and C5 pharmacophore elements.

34. The S1 pharmacophore group further comprises one, two, or three pharmacophore elements selected from the group consisting of C7, H2, and O4. C7 is a hydrophobic group; H2 is a hydrogen bond donor; O4 is a hydrogen bond receptor; The compound according to claim 33, wherein C7, H2, and O4 are coordinates within the ranges shown in Table 9.

35. The compound according to claim 34, wherein C7, H2, and O4 are coordinates within the ranges shown in Table 10.

36. The compound according to claim 35, wherein C7, H2, and O4 are coordinates within the ranges shown in Table 11.

37. The compound according to any one of claims 33 to 36, wherein the S1 pharmacophore group contains a C7 pharmacophore element.

38. The compound according to any one of claims 33 to 37, wherein the S1 pharmacophore group contains an H2 pharmacophore element.

39. The compound according to any one of claims 33 to 38, wherein the S1 pharmacophore group contains an O4 pharmacophore element.

40. The S2 pharmacophore group further comprises one or two pharmacophore elements selected from the group consisting of CA6 and O1. CA6 is an aromatic ring; O1 is a hydrogen bond acceptor; The compound according to any one of claims 26 to 39, wherein CA6 and O1 are coordinates within the range shown in Table 12.

41. The compound according to claim 40, wherein CA6 and O1 are coordinates within the range shown in Table 13.

42. The compound according to claim 41, wherein CA6 and O1 are coordinates within the range shown in Table 14.

43. The compound according to any one of claims 40 to 42, wherein the S1 pharmacophore group contains a CA6 pharmacophore element.

44. The compound according to any one of claims 40 to 43, wherein the S1 pharmacophore group contains an O1 pharmacophore element.

45. The compound according to any one of claims 26 to 44, wherein the S3 pharmacophore group comprises C2 and N2 pharmacophore elements.

46. The compound according to claim 45, wherein the S3 pharmacophore group further comprises an H3 pharmacophore element.

47. Further containing an S4 pharmacophore group; The S4 pharmacophore group contains a C4, CA2, CA4, or CA5 pharmacophore element; C4 is a hydrophobic group; CA2, CA4, and CA5 are aromatic rings; The compound according to any one of claims 26 to 46, wherein C4, CA2, CA4, and CA5 represent coordinates within the range shown in Table 15.

48. The compound according to claim 47, wherein C4, CA2, CA4, and CA5 represent coordinates within the ranges shown in Table 16.

49. The compound according to claim 48, wherein C4, CA2, CA4, and CA5 represent coordinates within the ranges shown in Table 17.

50. The compound according to any one of claims 47 to 49, wherein the S4 pharmacophore group contains C4.

51. The compound according to any one of claims 47 to 50, wherein the S4 pharmacophore group contains CA2.

52. The S4 pharmacophore group further comprises one, two, three, or four additional pharmacophore elements selected from the group consisting of C6, C7, CA4, and CA5. C6 and C7 are hydrophobic groups; CA4 and CA5 are aromatic rings; The compound according to claim 51, wherein C6, C7, CA4, and CA5 represent coordinates within the ranges shown in Table 18.

53. The compound according to claim 52, wherein C6, C7, CA4, and CA5 represent coordinates within the range shown in Table 19.

54. The compound according to claim 53, wherein C6, C7, CA4, and CA5 represent coordinates within the range shown in Table 20.

55. The compound according to any one of claims 47 to 54, wherein the S4 pharmacophore group contains a C6 pharmacophore element.

56. The compound according to any one of claims 47 to 55, wherein the S4 pharmacophore group contains a C7 pharmacophore element.

57. The compound according to any one of claims 47 to 56, wherein the S4 pharmacophore group contains a CA4 pharmacophore element.

58. The compound according to any one of claims 47 to 57, wherein the S4 pharmacophore group contains a CA5 pharmacophore element.

59. The compound according to any one of claims 26 to 58, further comprising an RM pharmacophore group; wherein the RM pharmacophore group comprises a CA3 pharmacophore element, and CA3 is an aromatic ring exhibiting coordinates within the range shown in Table 21.

60. The compound according to claim 59, wherein CA3 represents a coordinate within the range shown in Table 22.

61. The compound according to claim 60, wherein CA3 represents a coordinate within the range shown in Table 23.

62. The RM pharmacophore group further comprises one or two additional pharmacophore elements selected from the group consisting of H1 and O3. H1 is a hydrogen bond donor; O3 is a hydrogen bond acceptor; The compound according to any one of claims 59 to 61, wherein H1 and O3 are coordinates within the range shown in Table 24.

63. The compound according to claim 62, wherein H1 and O3 are coordinates within the ranges shown in Table 25.

64. The compound according to claim 63, wherein H1 and O3 are coordinates within the ranges shown in Table 26.

65. The compound according to any one of claims 62 to 64, wherein the RM pharmacophore group contains H1.

66. The compound according to any one of claims 62 to 65, wherein the RM pharmacophore group contains O3.

67. A pharmaceutical composition comprising a compound according to any one of claims 26 to 66 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

68. Compounds of formula (I-1) or their salts: During the ceremony, Cy 1A is unsubstituted or substituted C 6～10 aryl or unsubstituted or substituted 5- to 10-member heteroaryl; the Cy 1A ring atoms of the 5- to 10-member heteroaryl forming Cy consist of carbon atoms and one, two, or three heteroatoms selected from O, N, and S; the Cy 1A substituted C 6～10 aryl or substituted 5- to 10-member heteroaryl is R Cy1A , halogen, C 1～6 haloalkyl, CN, OR a11 , SR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)OR a11 , OC(O)R b11 , OC(O)NR c11 R d11 , NR c11 R d11 , NR c11 C(O)R b11 , NR c11 C(O)NR c11 R d11 , NR c11 C(O)OR a11 , C(=NR e11 )NR c11 R d11 , C(=NOR a11 )NR c11 R d11 , C(=NOC(O)R b11 )NR c11 R d11 , C(=NR e11 )NR c11 C(O)OR a11 , NR c11 C(=NR e11 )NR c11 R<000​​​​​​​​​​​​​​​​​​​​R d11 Substituted with one, two, three, four, or five substituents independently selected from the , and oxo; Each R Cy1A is independently C 1～6 alkyl, C 2～6 alkenyl, C 2～6 alkynyl, C 6～10 aryl, 5- to 10-membered heteroaryl, C 3～10 cycloalkyl, and 4- to 10-membered heterocycloalkyl, and the R Cy1A forming 5- to 10-membered heteroaryl or 4- to 10-membered heterocycloalkyl ring atoms consist of carbon atoms and one, two, three, or four heteroatoms selected from O, N, and S, and each C Cy1A forming R 1～6 alkyl, C 2～6 alkenyl, or C 2～6 alkynyl is independently unsubstituted or halogen, CN, OR a11 , SR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)OR a11 , OC(O)R b11 , OC(O)NR c11 R d11 , NR c11 R d11 , NR c11 C(O)R b11 , NR c11 C(O)NR c11 R d11 , NR c11 C(O)OR a11 , C(=NR e11 )NR c11 [[ID=六十二]]R d11 , NR c11 , C(=NR e11 )NR c11 R d11 , S(O)R b11 , S(O)NR c11 R d11 , S(O) 2 R b11 , NR c11 , S(O) 2 R b11 , S(O) 2 后添加的内容,原文中没有对应翻译,根据上下文推测可能是“2” , NR c11 R d11 , and are substituted with one, two, or three substituents independently selected from the oxo, R Cy1A Each C that forms 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Cycloalkyls and 4- to 10-membered heterocycloalkyls are independently unsubstituted or halogenated. 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 1～6 Haloalkyl, CN, OR a11 , SR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)OR a11 ,OC(O)R b11 , OC(O)NR c11 R d11 , NR c11 R d11 , NR c11 C(O)R b11 , NR c11 C(O)NR c11 R d11 , NR c11 C(O)OR a11 , C(=NR e11 )NR c11 R d11 , NR c11 C(=NR e11 )NR c11 R d11 , S(O)R b11 , S(O)NR c11 R d11 , S(O) 2 R b11 , NR c11 S(O) 2 R b11 , S(O) 2 NR c11 R d11 , and are substituted with one, two, or three substituents independently selected from the oxo; R 11 is H, or C 1～6 Alkyl, C 6～10 Aryl-C 1～6 Alkyl or 5-10 member heteroaryl-C 1～6 It is alkyl, R 11 C that forms 1～6 Alkyls are either unsubstituted or contain halogens, CN, OR a11 , SR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)OR a11 ,OC(O)R b11 , OC(O)NR c11 R d11 , NR c11 R d11 , NR c11 C(O)R b11 , NR c11 C(O)NR c11 R d11 , NR c11 C(O)OR a11 , C(=NR e11 )NR c11 R d11 , NR c11 C(=NR e11 )NR c11 R d11 , S(O)R b11 , S(O)NR c11 R d11 , S(O) 2 R b11 , NR c11 S(O) 2 R b11 , S(O) 2 NR c11 R d11 , and are substituted with one, two, or three substituents independently selected from the oxo, R 11 C that forms 6～10 Aryl-C 1～6 Alkyl or 5-10 member heteroaryl-C 1～6 Alkyl is either unsubstituted or C 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 1～6 Haloalkyl, CN, OR a11 , SR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)OR a11 ,OC(O)R b11 , OC(O)NR c11 R d11 , NR c11 R d11 , NR c11 C(O)R b11 , NR c11 C(O)NR c11 R d11 , NR c11 C(O)OR a11 , C(=NR e11 )NR c11 R d11 , NR c11 C(=NR e11 )NR c11 R d11 , S(O)R b11 , S(O)NR c11 R d11 , S(O) 2 R b11 , NR c11 S(O) 2 R b11 , S(O) 2 NR c11 R d11 , and are substituted with one, two, or three substituents independently selected from the oxo; R 12 is H or C 1～6 It is alkyl; or, R 11 and R 12 These, together with the groups to which they are bonded, form a 4- to 6-membered heterocycloalkyl ring; A 11 CR 13 R 15 or N; Each R 13 Cy 1B , (CR 13A R 13B ) n3 Cy 1B , (C 1～6 Alkilen)Cy 1B , (C 2～6 Alkenylene) Cy 1B , (C 2～6 Alkinylene)Cy 1B , or OCy 1B And R 13 C 1～6 Alkylene, C 2～6 Alkenylene, or C 2～6 The alkylylene component is either unsubstituted or contains halogen, CN, OR a11 , SR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)OR a11 ,OC(O)R b11 , OC(O)NR c11 R d11 , NR c11 R d11 , NR c11 C(O)R b11 , NR c11 C(O)NR c11 R d11 , NR c11 C(O)OR a11 , C(=NR e11 )NR c11 R d11 , NR c11 C(=NR e11 )NR c11 R d11 , S(O)R b11 , S(O)NR c11 R d11 , S(O) 2 R b11 , NR c11 S(O) 2 R b11 , S(O) 2 NR c11 R d11 Substituting with one, two, three, four, or five substituents independently selected from the group consisting of , and oxo; Each R 14 H and C are independent of each other. 1～6 Selected from alkyl groups; R 15 H, R 13 , C 1～6 Selected from alkyl and OH; R bonded to an adjacent carbon atom 14 R is bonded to pairs of groups or to adjacent carbon atoms. 14 Base and R 15 The pair with the base is the other R 14 Independent of the existence of R, together with it 14 pairs of groups or R 14 Base and R 15 The bond may be replaced by a bond connecting the adjacent carbon atom to which the group is bonded, thereby connecting the adjacent carbon atoms by a double bond; or, R bonded to the same carbon atom 14 R groups bonded to each other, or to the same carbon atom 13 Base and R 15 The pair with the base is the other R 14 Independent of the existence of R 14 pairs of groups or R 13 Base and R 15 The pair with the group forms a spirocondensation with the carbon atom it is bonded to. 3～10 A cycloalkyl ring or a 4- to 10-membered heterocycloalkyl ring may be formed, and the ring atoms of the formed 4- to 10-membered heterocycloalkyl ring consist of a carbon atom and one, two, or three heteroatoms selected from O, N, and S, and the spirocondensation C that is formed 3～10 Cycloalkyl rings or 4- to 10-membered heterocycloalkyl rings contain halogens, C 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, Haloalkyl, CN, OR a11 , SR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)OR a11 ,OC(O)R b11 , OC(O)NR c11 R d11 , NR c11 R d11 , NR c11 C(O)R b11 , NR c11 C(O)NR c11 R d11 , NR c11 C(O)OR a11 , C(=NR e11 )NR c11 R d11 , NR c11 C(=NR e11 )NR c11 R d11 , S(O)R b11 , S(O)NR c11 R d11 , S(O) 2 R b11 , NR c11 S(O) 2 R b11 , S(O) 2 NR c11 R d11 , and may be further substituted with one, two, or three substituents independently selected from the oxo; or, R bonded to an adjacent carbon atom 14 R is bonded to pairs of groups or to adjacent carbon atoms. 14 Base and R 15 The pair with the base is the other R 14 Independent of the existence of R 14 pairs of groups or R 14 Base and R 15 It condenses together with the adjacent carbon atom to which it is bonded with the group. 3～10 A cycloalkyl ring or a 4- to 10-membered heterocycloalkyl ring may be formed, and the ring atoms of the formed 4- to 10-membered heterocycloalkyl ring consist of a carbon atom and one, two, or three heteroatoms selected from O, N, and S, and the formed condensation C 3～10 Cycloalkyl rings or 4- to 10-membered heterocycloalkyl rings contain halogens, C 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, Haloalkyl, CN, OR a11 , SR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)OR a11 ,OC(O)R b11 , OC(O)NR c11 R d11 , NR c11 R d11 , NR c11 C(O)R b11 , NR c11 C(O)NR c11 R d11 , NR c11 C(O)OR a11 , C(=NR e11 )NR c11 R d11 , NR c11 C(=NR e11 )NR c11 R d11 , S(O)R b11 , S(O)NR c11 R d11 , S(O) 2 R b11 , NR c11 S(O) 2 R b11 , S(O) 2 NR c11 R d11 , and may be further substituted with one, two, or three substituents independently selected from the oxo; or, Four R atoms bonded to two adjacent carbon atoms 14 A group of R groups, or two R groups bonded to two adjacent carbon atoms 14 Base and 1 R 13 Base and 1 R 15 The group of elements is the other R 14 Independent of the existence of the four R 14 A group of elements or two R 14 Base and 1 R 13 Base and 1 R 15 The group of atoms combines with the two adjacent carbon atoms to which it is bonded, forming a condensed C 6～10 Aryl ring or 5-10 membered heteroaryl ring, C 3～10 A cycloalkyl ring or a 4- to 10-membered heterocycloalkyl ring may be formed, and the ring atoms of the formed 5- to 10-membered heteroaryl ring or 4- to 10-membered heterocycloalkyl ring consist of carbon atoms and one, two, or three heteroatoms selected from O, N, and S, and the formed condensation C 6～10 Aryl ring or 5-10 membered heteroaryl ring, C 3～10 A cycloalkyl ring, or a 4- to 10-membered heterocycloalkyl ring, is a halogen, C 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, Haloalkyl, CN, OR a11 , SR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)OR a11 ,OC(O)R b11 , OC(O)NR c11 R d11 , NR c11 R d11 , NR c11 C(O)R b11 , NR c11 C(O)NR c11 R d11 , NR c11 C(O)OR a11 , C(=NR e11 )NR c11 R d11 , NR c11 C(=NR e11 )NR c11 R d11 , S(O)R b11 , S(O)NR c11 R d11 , S(O) 2 R b11 , NR c11 S(O) 2 R b11 , S(O) 2 NR c11 R d11 , and may be further substituted with one, two, or three substituents independently selected from the oxo; n1 is either 1 or 2; n2 is 0, 1, or 2; However, the sum of n1 and n2 is 1, 2, or 3; However, if n1 is 1 or n2 is 0, A 11 CR 13 R 15 and; n3 is 0, 1, or 2; Each R 13A H or C 1～6 It is alkyl; Each R 13B H or C 1～6 It is alkyl; or, R bonded to the same carbon atom 13A and R 13B is any other R 13A base and R 13B Originally independent, then together - (CH 2 ) 2～5 - may be formed, thereby forming a 3- to 6-membered cycloalkyl ring; Cy 1B is either non-substituted or substituted C 6～10 Aryl, unsubstituted or substituted 5- to 10-membered heteroaryl, unsubstituted or substituted C 3～10 Cycloalkyl, or unsubstituted or substituted 4- to 10-membered heterocycloalkyl; Cy 1B The ring atoms of the 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl groups that form the ring consist of one, two, or three heteroatoms selected from carbon atoms and O, N, and S; Cy 1B Substitution C that forms 6～10 Aryl, substituted 5-10 member heteroaryl, substituted C 3～10 Cycloalkyls, or substituted 4- to 10-membered heterocycloalkyls, R Cy1B , halogen, C 1～6 Haloalkyl, CN, OR a11 , SR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)OR a11 ,OC(O)R b11 , OC(O)NR c11 R d11 , NR c11 R d11 , NR c11 C(O)R b11 , NR c11 C(O)NR c11 R d11 , NR c11 C(O)OR a11 , C(=NR e11 )NR c11 R d11 , C(=NOR a11 )NR c11 R d11 , C(=NOC(O)R b11 )NR c11 R d11 , C(=NR e11 )NR c11 C(O)OR a11 , NR c11 C(=NR e11 )NR c11 R d11 , S(O)R b11 , S(O)NR c11 R d11 , S(O) 2 R b11 , NR c11 S(O) 2 R b11 , S(O) 2 NR c11 R d11 Substituted with one, two, three, four, or five substituents independently selected from the , and oxo; Each R Cy1B C is independent 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Selected from cycloalkyl and 4- to 10-membered heterocycloalkyl groups, R Cy1B The ring atoms of the 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl groups that form the ring consist of one, two, or three heteroatoms selected from carbon atoms and O, N, and S; R Cy1B Each C that forms 1～6 Alkyl, C 2～6 Alkenyl, or C 2～6 Alkynnyls are independently unsubstituted or halogen, CN, OR a11 , SR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)OR a11 ,OC(O)R b11 , OC(O)NR c11 R d11 , NR c11 R d11 , NR c11 C(O)R b11 , NR c11 C(O)NR c11 R d11 , NR c11 C(O)OR a11 , C(=NR e11 )NR c11 R d11 , NR c11 C(=NR e11 )NR c11 R d11 , S(O)R b11 , S(O)NR c11 R d11 , S(O) 2 R b11 , NR c11 S(O) 2 R b11 , S(O) 2 NR c11 R d11 , and are substituted with one, two, or three substituents independently selected from the oxo; R Cy1B Each C that forms 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Cycloalkyls and 4- to 10-membered heterocycloalkyls are independently unsubstituted or halogenated. 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 1～6 Haloalkyl, CN, OR a11 , SR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)OR a11 ,OC(O)R b11 , OC(O)NR c11 R d11 , NR c11 R d11 , NR c11 C(O)R b11 , NR c11 C(O)NR c11 R d11 , NR c11 C(O)OR a11 , C(=NR e11 )NR c11 R d11 , NR c11 C(=NR e11 )NR c11 R d11 , S(O)R b11 , S(O)NR c11 R d11 , S(O) 2 R b11 , NR c11 S(O) 2 R b11 , S(O) 2 NR c11 R d11 , and are substituted with one, two, or three substituents independently selected from the oxo; R 16 H, Cy 1C , C 1～6 Alkyl, C 2～6 Alkenyl, or C 2～6 It is alkinyl, R 16 C that forms 1～6 Alkyl, C 2～6 Alkenyl, or C 2～6 Alkinyl is either not substituted or Cy 1C , halogen, CN, OR a11 , SR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)OR a11 ,OC(O)R b11 , OC(O)NR c11 R d11 , NR c11 R d11 , NR c11 C(O)R b11 , NR c11 C(O)NR c11 R d11 , NR c11 C(O)OR a11 , C(=NR e11 )NR c11 R d11 , NR c11 C(=NR e11 )NR c11 R d11 , S(O)R b11 , S(O)NR c11 R d11 , S(O) 2 R b11 , NR c11 S(O) 2 R b11 , S(O) 2 NR c11 R d11 It is substituted with one, two, three, four, or five substituents selected from the group consisting of , and oxo, however, R 16 One or fewer of the substituents are Cy 1C and; Cy 1C is either non-substituted or substituted C 6～10 Aryl, unsubstituted or substituted 5- to 10-membered heteroaryl, unsubstituted or substituted C 3～10 Cycloalkyl, or unsubstituted or substituted 4- to 10-membered heterocycloalkyl; Cy 1C The ring atoms of the 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl groups that form the ring consist of one, two, or three heteroatoms selected from carbon atoms and O, N, and S; Cy 1C Substitution C that forms 6～10 Aryl, substituted 5-10 member heteroaryl, substituted C 3～10 Cycloalkyls, or substituted 4- to 10-membered heterocycloalkyls, R Cy1C , halogen, C 1～6 Haloalkyl, CN, OR a11 , SR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)OR a11 ,OC(O)R b11 , OC(O)NR c11 R d11 , NR c11 R d11 , NR c11 C(O)R b11 , NR c11 C(O)NR c11 R d11 , NR c11 C(O)OR a11 , C(=NR e11 )NR c11 R d11 , C(=NOR a11 )NR c11 R d11 , C(=NOC(O)R b11 )NR c11 R d11 , C(=NR e11 )NR c11 C(O)OR a11 , NR c11 C(=NR e11 )NR c11 R d11 , S(O)R b11 , S(O)NR c11 R d11 , S(O) 2 R b11 , NR c11 S(O) 2 R b11 , S(O) 2 NR c11 R d11 Substituted with one, two, three, four, or five substituents independently selected from the , and oxo; Each R Cy1C C is independent 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Selected from cycloalkyl and 4- to 10-membered heterocycloalkyl groups, R Cy1C The ring atoms of the 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl groups that form the ring consist of one, two, or three heteroatoms selected from carbon atoms and O, N, and S; R Cy1C Each C that forms 1～6 Alkyl, C 2～6 Alkenyl, or C 2～6 Alkynnyls are independently unsubstituted or halogen, CN, OR a11 , SR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)OR a11 ,OC(O)R b11 , OC(O)NR c11 R d11 , NR c11 R d11 , NR c11 C(O)R b11 , NR c11 C(O)NR c11 R d11 , NR c11 C(O)OR a11 , C(=NR e11 )NR c11 R d11 , NR c11 C(=NR e11 )NR c11 R d11 , S(O)R b11 , S(O)NR c11 R d11 , S(O) 2 R b11 , NR c11 S(O) 2 R b11 , S(O) 2 NR c11 R d11 , and are substituted with one, two, or three substituents independently selected from the oxo; R Cy1C Each C that forms 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Cycloalkyls and 4- to 10-membered heterocycloalkyls are independently unsubstituted or halogenated. 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 1～6 Haloalkyl, CN, OR a11 , SR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)OR a11 ,OC(O)R b11 , OC(O)NR c11 R d11 , NR c11 R d11 , NR c11 C(O)R b11 , NR c11 C(O)NR c11 R d11 , NR c11 C(O)OR a11 , C(=NR e11 )NR c11 R d11 , NR c11 C(=NR e11 )NR c11 R d11 , S(O)R b11 , S(O)NR c11 R d11 , S(O) 2 R b11 , NR c11 S(O) 2 R b11 , S(O) 2 NR c11 R d11 , and are substituted with one, two, or three substituents independently selected from the oxo; R a11 , R b11 , R c11 , and R d11 H and C are independent of each other. 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 6～10 Ariel, C 3～7 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6～10 Aryl-C 1～3 Alkyl, 5-10 member heteroaryl-C 1～3 Alkyl, C 3～7 Cycloalkyl-C 1～3 Alkyl and 4- to 10-membered heterocycloalkyl-C 1～3 Selected from alkyl groups, R a11 , R b11 , R c11 , and R d11 The C that forms 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 6～10 Ariel, C 3～7 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6～10 Aryl-C 1～3 Alkyl, 5-10 member heteroaryl-C 1～3 Alkyl, C 3～7 Cycloalkyl-C 1～3 Alkyl and 4- to 10-membered heterocycloalkyl-C 1～3 Each alkyl group is C 1～6 Alkyl, Halo, CN, OR a12 , SR a12 , C(O)R b12 , C(O)NR c12 R d12 , C(O)OR a12 ,OC(O)R b12 , OC(O)NR c12 R d12 , NR c12 R d12 , NR c12 C(O)R b12 , NR c12 C(O)NR c12 R d12 , NR c12 C(O)OR a12 , C(=NR e12 )NR c12 R d12 , NR c12 , C(=NR e12 )NR c12 R d12 , S(O)R b12 , S(O)NR c12 R d12 , S(O) 2 R b12 , NR c12 , S(O) 2 R b12 , S(O) 2 , NR c12 R d12 and may be substituted with one, two, three, four, or five substituents independently selected from oxo; or, R bonded to the same N atom c11 and R d11 These together with the N atom to which they are both bonded form a 4-membered, 5-membered, 6-membered, or 7-membered heterocycloalkyl group or a 5-membered heteroaryl group, each with C 1～6 Alkyl, Halo, CN, OR a12 , SR a12 , C(O)R b12 , C(O)NR c12 R d12 , C(O)OR a12 ,OC(O)R b12 , OC(O)NR c12 R d12 , NR c12 R d12 , NR c12 C(O)R b12 , NR c12 C(O)NR c12 R d12 , NR c12 C(O)OR a12 , C(=NR e12 )NR c12 R d12 , NR c12 C(=NR e12 )NR c12 R d12 , S(O)R b12 , S(O)NR c12 R d12 , S(O) 2 R b12 , NR c12 S(O) 2 R b12 , S(O) 2 NR c12 R d12 , and may be substituted with one, two, or three substituents independently selected from the oxo; R a12 、R b12 、R c12 、and R d12 are each independently H, C 1～6 alkyl, C 1～6 haloalkyl, C 2～6 alkenyl, C 2～6 alkynyl, phenyl, C 3～7 cycloalkyl, 5- to 6-membered heteroaryl, 4- to 7-membered heterocycloalkyl, phenyl-C 1～3 alkyl, 5- to 6-membered heteroaryl-C 1～3 alkyl, C 3～7 cycloalkyl-C 1～3 alkyl, and 4- to 7-membered heterocycloalkyl-C 1～3 alkyl, selected from R a12 、R b12 、R c12 、and R d12 forming the C 1～6 alkyl, C 1～6 haloalkyl, C 2～6 alkenyl, C 2～6 alkynyl, phenyl, C 3～7 cycloalkyl, 5- to 6-membered heteroaryl, 4- to 7-membered heterocycloalkyl, phenyl-C 1～3 alkyl, 5- to 6-membered heteroaryl-C 1～3 alkyl, C 3～7 cycloalkyl-C 1～3 alkyl, and 4- to 7-membered heterocycloalkyl-C 1～3 alkyl are each independently optionally substituted with one, two, or three substituents selected from OH, CN, amino, NH(C 1～6 alkyl), N(C 1～6 alkyl) 2 、halo, C 1～6 alkyl, C 1～6 alkoxy, C 1～6 haloalkyl, C 1～6 haloalkoxy, and oxo; or, R bonded to the same N atom c12 and R d12 These, together with the N atom to which they are both bonded, form a 4-membered, 5-membered, 6-membered, or 7-membered heterocycloalkyl group or a 5-membered heteroaryl group, each of which is either unsubstituted or OH, CN, amino, NH(C) 1～6 Alkyl), N(C 1～6 Alkyl) 2 Hello, C 1～6 Alkyl, C 1～6 Alkoxy, C 1～6 Haloalkyl, C 1～6 Substituted with one, two, or three substituents independently selected from haloalkoxys and oxos; R e11 and R e12 These are H, CN, or NO, respectively, independently. 2 That is the case.

69. Equation (I-2): The compound according to claim 68, or a salt thereof.

70. Cy 1A The compound or salt thereof according to claim 68 or 69, wherein is unsubstituted or substituted aryl.

71. Cy 1A The compound or salt thereof according to claim 70, wherein is an unsubstituted or substituted phenyl.

72. Cy 1A The compound or a salt thereof according to claim 71, wherein is a substituted phenyl.

73. Cy 1A at least one OR a11 or at least one C(=NR) e11 )NR c11 R d11 , C(=NOR a11 )NR c11 R d11 , C(=NOC(O)R b11 )NR c11 R d11 , or C(=NR e11 )NR c11 C(O)OR a11 A compound or salt thereof according to any one of claims 68 to 72, which is substituted with [the compound or salt thereof].

74. Cy 1A at least one OR a11 It is replaced with and C 1～6 Alkyl, C 1～6 A compound or salt thereof according to any one of claims 68 to 73, substituted with at least one further substituent selected from the group consisting of haloalkyls and halogens.

75. Cy 1A It is substituted with at least one OH group, and C 1～6 Alkyl, C 1～6 A compound or salt thereof according to any one of claims 68 to 74, substituted with at least one further substituent selected from the group consisting of haloalkyls and halogens.

76. Cy 1A Preferably at position 4, at least one C(=NR e11 )NR c11 R d11 , C(=NOR a11 )NR c11 R d11 , C(=NOC(O)R b11 )NR c11 R d11 , C(=NR e11 )NR c11 C(O)OR a11 A compound or salt thereof according to any one of claims 68 to 75, which is substituted with [the compound or salt thereof].

77. Cy 1A Preferably at position 4, at least one C(=NR e11 )NR c11 R d11 A compound or salt thereof according to claim 76, which is substituted with [the compound or salt of the of the claim 76, which is substituted with [the compound or salt of the compound].

78. Cy 1A Preferably at position 4, at least one C(=NH)NH 2 A compound or salt thereof according to claim 77, which is substituted with [the compound or salt].

79. Cy 1A The formula is as follows: The compound or salt thereof according to claim 72, which is any one of the above.

80. Cy 1A In the formula defining R, Cy1A C 1～6 The compound or a salt thereof according to claim 79, wherein the compound is alkyl, for example methyl, or halogen, for example Cl or Br, or amino.

81. Cy 1A The formula is as follows: The compound or salt thereof according to claim 72, which is any one of the above.

82. Cy 1A In the formula defining R a11 C 1～6 Alkyl, for example, methyl, R b11 C 1～6 Alkyl, for example, methyl, R b11 C 1～6 Haloalkyls, for example, trifluoromethyl, R c11 The compound or a salt thereof according to claim 81, wherein is alkyl, for example, methyl.

83. Cy 1A The compound or salt thereof according to claim 68 or 69, wherein is unsubstituted or substituted heteroaryl.

84. Cy 1A The compound or salt thereof according to claim 83, wherein is unsubstituted or substituted pyridine-3-yl, 1H-pyrrolo[2,3-b]pyridine-5-yl, or 1H-benzo[d]imidazole-6-yl.

85. Cy 1A The formula is as follows: The compound according to claim 83 or a salt thereof, which is any one of the above.

86. Cy 1A Each R in the formula defining Cy1A C 1～6 The compound or salt thereof according to claim 85, wherein the compound is an alkyl group, for example methyl or ethyl, preferably methyl, or a halogen, for example F, Cl, or Br, preferably Cl, or amino.

87. Cy 1A Each R bonded to nitrogen in the formula defining the Cy1A C 1～6 The compound or a salt thereof according to claim 85 or 86, wherein the compound is alkyl, for example, methyl or ethyl.

88. R 11 C 1～6 A compound or salt thereof according to any one of claims 68 to 87, wherein the compound is alkyl.

89. R 11 The compound or a salt thereof according to claim 88, wherein the compound is methyl.

90. R 11 A compound or salt thereof according to any one of claims 68 to 87, wherein is H.

91. R 12 A compound or salt thereof according to any one of claims 68 to 90, wherein is H.

92. R 12 C 1～6 A compound or salt thereof according to any one of claims 68 to 90, wherein the compound is alkyl, for example, methyl or ethyl, preferably methyl.

93. R 11 and R 12 The compound or salt thereof according to any one of claims 68 to 87, wherein they, together with the groups to which they are bonded, form a 4-6 membered heterocycloalkyl ring.

94. A compound or salt thereof according to any one of claims 68 to 93, wherein n1 is 1.

95. A compound or salt thereof according to any one of claims 68 to 93, wherein n1 is 2.

96. A compound or salt thereof according to any one of claims 68 to 95, wherein n2 is 0.

97. A compound or salt thereof according to any one of claims 68 to 95, wherein n2 is 1.

98. A compound or salt thereof according to any one of claims 68 to 95, wherein n2 is 2.

99. The following equations (I-1a) to (I-1f) and (I-2a) to (I-2r): A compound or salt thereof according to any one of claims 68 to 98, which matches any one of the above.

100. The following formulas (I-1g) to (I-1o) and (I-2aa) to (I-2az): A compound or salt thereof according to any one of claims 68 to 99, which matches any one of the above.

101. The following equations (I-3) to (I-9): A compound or salt thereof according to any one of claims 68 to 100, which matches any one of the above.

102. The following equations (I-3a) to (I-3k): A compound or salt thereof according to any one of claims 68 to 101, which matches any one of the above.

103. The following equations (I-4a) to (I-4bf): A compound or salt thereof according to any one of claims 68 to 101, which matches any one of the above.

104. The following equations (I-5a) to (I-5u): A compound or salt thereof according to any one of claims 68 to 101, which matches any one of the above.

105. The following equations (I-6a) to (I-6cw): A compound or salt thereof according to any one of claims 68 to 101, which matches any one of the above.

106. The following equations (I-7a) to (I-7co): A compound or salt thereof according to any one of claims 68 to 101, which matches any one of the above.

107. The following equations (I-8a) to (I-8z): A compound or salt thereof according to any one of claims 68 to 101, which matches any one of the above.

108. The following equations (I-9a) to (I-9z): A compound or salt thereof according to any one of claims 68 to 101, which matches any one of the above.

109. R 13 Cy 1B The compound or salt thereof according to any one of claims 68 to 108.

110. R 13 (C 1～6 Alkilen)Cy 1B , (C 2～6 Alkenylene) Cy 1B , or (C 2～6 Alkinylene)Cy 1B The compound or salt thereof according to any one of claims 68 to 108.

111. R 13 C 1～6 Alkylene, C 2～6 Alkenylene, or C 2～6 The compound or salt thereof according to claim 110, wherein the alkynylene component is not substituted.

112. R 13 (CR 13A R 13B ) n3 Cy 1B The compound or salt thereof according to any one of claims 68 to 108.

113. Each R 13A The compound or a salt thereof according to claim 112, wherein is H.

114. Each R 13B The compound or a salt thereof according to claim 112, wherein is H.

115. A compound or salt thereof according to any one of claims 68 to 114, wherein n3 is 0.

116. A compound or salt thereof according to any one of claims 68 to 114, wherein n3 is 1.

117. A compound or salt thereof according to any one of claims 68 to 114, wherein n3 is 2.

118. R 13 (CH 2 ) 0～2 Cy 1B The compound or salt thereof according to any one of claims 68 to 114.

119. R 13 CH 2 Cy 1B The compound or salt thereof according to any one of claims 68 to 114.

120. R 13 CH 2 CH 2 Cy 1B The compound or salt thereof according to any one of claims 68 to 114.

121. R 13 OCy 1B The compound or salt thereof according to any one of claims 68 to 108.

122. Cy 1B is non-substituted C 6～10 A compound or salt thereof according to any one of claims 68 to 121, wherein the compound is an aryl compound.

123. Cy 1B The compound or a salt thereof according to claim 122, wherein is an unsubstituted phenyl.

124. Cy 1B The compound or salt thereof according to claim 122, wherein is an unsubstituted naphthyl, for example, 1-naphthyl or 2-naphthyl.

125. Cy 1B The compound or salt thereof according to any one of claims 68 to 124, wherein is an unsubstituted 5- to 10-membered heteroaryl compound.

126. Cy 1B The compound or salt thereof according to claim 125, wherein is an unsubstituted pyridyl, for example, an unsubstituted 2-, 3-, or 4-pyridyl, or an unsubstituted quinolyl, for example, an unsubstituted 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl.

127. Cy 1B Substitution C 6～10 A compound or salt thereof according to any one of claims 68 to 121, wherein the compound is an aryl compound.

128. Cy 1B The compound or a salt thereof according to claim 127, wherein is a substituted phenyl.

129. Cy 1B The compound or salt thereof according to claim 128, wherein is biphenylyl (i.e., phenyl-substituted phenyl), for example, 2-, 3-, or 4-biphenylyl.

130. Cy 1B The compound or salt thereof according to claim 129, wherein is a substituted naphthyl, for example, 1-naphthyl or 2-naphthyl.

131. Cy 1B A compound or salt thereof according to any one of claims 68 to 121, wherein is a substituted 5- to 10-membered heteroaryl compound.

132. Cy 1B The compound or salt thereof according to claim 131, wherein is a substituted pyridyl, for example, a substituted 2-, 3-, or 4-pyridyl, or a substituted quinolyl, for example, a substituted 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl.

133. Cy 1B However, R Cy1B , halogen, and C 1～6 Each R is substituted with one, two, three, four, or five substituents independently selected from the haloalkyl groups; Cy1B C 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl and C 6～10 Selected from aryl or 5- to 10-membered heteroaryl, R Cy1B Each C that forms 6～10 Aryl or 5- to 10-membered heteroaryl compounds, either unsubstituted or halogenated, C 1～6 Alkyl, C 2～6 Alkenil, C 2～6 A compound or salt thereof according to any one of claims 127 to 132, substituted with one, two, or three substituents independently selected from alkynyl and haloalkyl groups.

134. R 13 The formula is as follows: A compound or salt thereof according to any one of claims 68 to 133, selected from the groups of the following.

135. R 13 R in the expression representing Cy1B C 1～6 The compound or salt thereof according to claim 134, wherein the alkyl is, for example, methyl or ethyl, preferably methyl, or the halogen is, for example, fluorine or chlorine, preferably fluorine.

136. R 13 R in the expression representing Cy1B C 1～6 The compound or a salt thereof according to claim 134, wherein the compound is alkyl, for example, methyl or ethyl, preferably methyl.

137. R 13 R in the expression representing Cy1B The compound or salt thereof according to claim 134, wherein is a halogen, for example, fluorine or chlorine, preferably fluorine.

138. One or fewer R 14 A compound or salt thereof according to any one of claims 68 to 137, wherein the compound is other than hydrogen.

139. One or fewer R 14 is anything other than hydrogen, and one R 14 C 1～6 The compound or a salt thereof according to claim 138, wherein the compound is alkyl, for example, methyl.

140. Each R 14 The compound or salt thereof according to claim 139, wherein the compound is hydrogen.

141. A 11 A compound or salt thereof according to any one of claims 68 to 140, wherein is N.

142. R 15 A compound or salt thereof according to any one of claims 68 to 141, wherein the compound is hydrogen.

143. R 15 C 1～6 A compound or salt thereof according to any one of claims 68 to 141, wherein the compound is alkyl, for example, methyl.

144. R 15 A compound or salt thereof according to any one of claims 68 to 141, wherein the compound is a hydroxyl group.

145. R 16 A compound or salt thereof according to any one of claims 68 to 144, wherein the compound is hydrogen.

146. R 16 C is either non-substitutive or substituted. 1～6 Alkyl, C 2～6 Alkenyl, or C 2～6 A compound or salt thereof according to any one of claims 68 to 144, wherein the compound is an alkynyl.

147. R 16 is non-substituted C 1～6 The compound or a salt thereof according to claim 146, wherein the compound is alkyl, for example, methyl.

148. R 16 Substitution C 1～6 The compound or salt thereof according to claim 146, wherein it is alkyl.

149. R 16 Substitution C that forms 1～6 Alkyl, halogen, CN, C(O)NR c11 R d11 , and C(O)OR a11 The compound or salt thereof according to claim 148, substituted with one, two, three, four, or five substituents selected from the group consisting of, for example, one, two, or three, preferably one substituent.

150. R 16 (CH 2 ) 1～6 C(O)OR a11 The compound or salt thereof according to claim 149.

151. R 16 R defines a11 is H or C 1～6 The compound or a salt thereof according to claim 150, wherein the compound is alkyl, for example, methyl.

152. R 16 R defines a11 The compound or a salt thereof according to claim 150, wherein is H.

153. R a11 , R b11 , R c11 , and R d11 , R a12 , R b12 , R c12 , and R d12 H and C are independent of each other. 1～6 A compound or salt thereof according to any one of claims 68 to 152, selected from alkyl groups.

154. Each R e11 and each R e12 A compound or salt thereof according to any one of claims 68 to 85153, wherein is H.

155. A pharmaceutical composition comprising a compound according to any one of claims 68 to 154 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

156. Compounds of formula (IIA) or (IIB), or their salts: During the ceremony, Cy 2A is either non-substituted or substituted C 6～10 It is an aryl or unsubstituted or substituted 5- to 10-membered heteroaryl; Cy 2A The ring atoms of the 5-10 membered heteroaryl that form the Cy 2A Substitution C that forms 6～10 Aryl or substituted 5-10 member heteroaryls are R Cy2A , halogen, C 1～6 Haloalkyl, CN, OR a21 , SR a21 , C(O)R b21 , C(O)NR c21 R d21 , C(O)OR a21 ,OC(O)R b21 , OC(O)NR c21 R d21 , NR c21 R d21 , NR c21 C(O)R b21 , NR c21 C(O)NR c21 R d21 , NR c21 C(O)OR a21 , C(=NR e21 )NR c21 R d21 , C(=NOR a21 )NR c21 R d21 , C(=NOC(O)R b21 )NR c21 R d21 , C(=NR e21 )NR c21 C(O)OR a21 , NR c21 C(=NR e21 )NR c21 R d21 , S(O)R b21 , S(O)NR c21 R d21 , S(O) 2 R b21 , NR c21 S(O) 2 R b21 , S(O) 2 NR c21 R d21 Substituted with one, two, three, four, or five substituents independently selected from the , and oxo; Each R Cy2A C is independent 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Selected from cycloalkyl and 4- to 10-membered heterocycloalkyl groups, R Cy2A The ring atoms of the 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl groups that form the ring consist of one, two, three, or four heteroatoms selected from carbon atoms and O, N, and S, R Cy2A Each C that forms 1～6 Alkyl, C 2～6 Alkenyl, or C 2～6 Alkynnyls are independently unsubstituted or halogen, CN, OR a21 , SR a21 , C(O)R b21 , C(O)NR c21 R d21 , C(O)OR a21 ,OC(O)R b21 , OC(O)NR c21 R d21 , NR c21 R d21 , NR c21 C(O)R b21 , NR c21 C(O)NR c21 R d21 , NR c21 C(O)OR a21 , C(=NR e21 )NR c21 R d21 , NR c21 C(=NR e21 )NR c21 R d21 , S(O)R b21 , S(O)NR c21 R d21 , S(O) 2 R b21 , NR c21 S(O) 2 R b21 , S(O) 2 NR c21 R d21 , and are substituted with one, two, or three substituents independently selected from the oxo, R Cy2A Each C that forms 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Cycloalkyls and 4- to 10-membered heterocycloalkyls are independently unsubstituted or halogenated. 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 1～6 Haloalkyl, CN, OR a21 , SR a21 , C(O)R b21 , C(O)NR c21 R d21 , C(O)OR a21 ,OC(O)R b21 , OC(O)NR c21 R d21 , NR c21 R d21 , NR c21 C(O)R b21 , NR c21 C(O)NR c21 R d21 , NR c21 C(O)OR a21 , C(=NR e21 )NR c21 R d21 , NR c21 C(=NR e21 )NR c21 R d21 , S(O)R b21 , S(O)NR c21 R d21 , S(O) 2 R b21 , NR c21 S(O) 2 R b21 , S(O) 2 NR c21 R d21 , and are substituted with one, two, or three substituents independently selected from the oxo; R 21 is H, or C 1～6 Alkyl, C 6～10 Aryl-C 1～6 Alkyl or 5-10 member heteroaryl-C 1～6 It is alkyl, R 21 C that forms 1～6 Alkyls are either unsubstituted or contain halogens, CN, OR a21 , SR a21 , C(O)R b21 , C(O)NR c21 R d21 , C(O)OR a21 ,OC(O)R b21 , OC(O)NR c21 R d21 , NR c21 R d21 , NR c21 C(O)R b21 , NR c21 C(O)NR c21 R d21 , NR c21 C(O)OR a21 , C(=NR e21 )NR c21 R d21 , NR c21 C(=NR e21 )NR c21 R d21 , S(O)R b21 , S(O)NR c21 R d21 , S(O) 2 R b21 , NR c21 S(O) 2 R b21 , S(O) 2 NR c21 R d21 , and are substituted with one, two, or three substituents independently selected from the oxo, R 21 C that forms 6～10 Aryl-C 1～6 Alkyl or 5-10 member heteroaryl-C 1～6 Alkyl is either unsubstituted or C 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 1～6 Haloalkyl, CN, OR a21 , SR a21 , C(O)R b21 , C(O)NR c21 R d21 , C(O)OR a21 ,OC(O)R b21 , OC(O)NR c21 R d21 , NR c21 R d21 , NR c21 C(O)R b21 , NR c21 C(O)NR c21 R d21 , NR c21 C(O)OR a21 , C(=NR e21 )NR c21 R d21 , NR c21 C(=NR e21 )NR c21 R d21 , S(O)R b21 , S(O)NR c21 R d21 , S(O) 2 R b21 , NR c21 S(O) 2 R b21 , S(O) 2 NR c21 R d21 , and are substituted with one, two, or three substituents independently selected from the oxo; R 22 is H or C 1～6 It is alkyl; or, R 21 and R 22 These, together with the groups to which they are bonded, form a 4- to 6-membered heterocycloalkyl ring; A 23 is N or NR 23 and; A 24 CR 24 , N, or NR 24 and; A 26 CR 26 Or it is S; however, A in equation (IIA) 23 , A 24 , and A 26 is, A 23 , A 24 , and A 26 The ring containing the symbol is selected such that it is a heteroaryl ring. This represents an aromatic ring (normalized) bond; R 23 is H or C 1～6 It is alkyl; R 24 H, C 1～6 Alkyl or phenyl; R 25 is Cy 2B , (CR 25A R 25B ) n25 Cy 2B , (C 1～6 Alkilen)Cy 2B , (C 2～6 Alkenylene) Cy 2B , or (C 2～6 Alkinylene)Cy 2B And R 25 C 1～6 Alkylene, C 2～6 Alkenylene, or C 2～6 The alkylylene component is either unsubstituted or contains halogen, CN, OR a21 , SR a21 , C(O)R b21 , C(O)NR c21 R d21 , C(O)OR a21 ,OC(O)R b21 , OC(O)NR c21 R d21 , NR c21 R d21 , NR c21 C(O)R b21 , NR c21 C(O)NR c21 R d21 , NR c21 C(O)OR a21 , C(=NR e21 )NR c21 R d21 , NR c21 C(=NR e21 )NR c21 R d21 , S(O)R b21 , S(O)NR c21 R d21 , S(O) 2 R b21 , NR c21 S(O) 2 R b21 , S(O) 2 NR c21 R d21 Substituting with one, two, three, four, or five substituents independently selected from the group consisting of , and oxo; R 26 is H or C 1～6 It is alkyl; Each R 25A is H or C 1～6 It is alkyl; Each R 25B is H or C 1～6 It is alkyl; n25 is 0, 1, or 2; Cy 2B is either non-substituted or substituted C 6～10 Aryl, unsubstituted or substituted 5- to 10-membered heteroaryl, unsubstituted or substituted C 3～10 Cycloalkyl, or unsubstituted or substituted 4- to 10-membered heterocycloalkyl; Cy 2B The ring atoms of the 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl groups that form the ring consist of one, two, or three heteroatoms selected from carbon atoms and O, N, and S; Cy 2B Substitution C that forms 6～10 Aryl, substituted 5-10 member heteroaryl, substituted C 3～10 Cycloalkyls, or substituted 4- to 10-membered heterocycloalkyls, R Cy2B , halogen, C 1～6 Haloalkyl, CN, OR a21 , SR a21 , C(O)R b21 , C(O)NR c21 R d21 , C(O)OR a21 ,OC(O)R b21 , OC(O)NR c21 R d21 , NR c21 R d21 , NR c21 C(O)R b21 , NR c21 C(O)NR c21 R d21 , NR c21 C(O)OR a21 , C(=NR e21 )NR c21 R d21 , C(=NOR a21 )NR c21 R d21 , C(=NOC(O)R b21 )NR c21 R d21 , C(=NR e21 )NR c21 C(O)OR a21 , NR c21 C(=NR e21 )NR c21 R d21 , S(O)R b21 , S(O)NR c21 R d21 , S(O) 2 R b21 , NR c21 S(O) 2 R b21 , S(O) 2 NR c21 R d21 Substituted with one, two, three, four, or five substituents independently selected from the , and oxo; Each R Cy2B C is independent 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Selected from cycloalkyl and 4- to 10-membered heterocycloalkyl groups, R Cy2B The ring atoms of the 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl groups that form the ring consist of one, two, or three heteroatoms selected from carbon atoms and O, N, and S; R Cy2B Each C that forms 1～6 Alkyl, C 2～6 Alkenyl, or C 2～6 Alkynnyls are independently unsubstituted or halogen, CN, OR a21 , SR a21 , C(O)R b21 , C(O)NR c21 R d21 , C(O)OR a21 ,OC(O)R b21 , OC(O)NR c21 R d21 , NR c21 R d21 , NR c21 C(O)R b21 , NR c21 C(O)NR c21 R d21 , NR c21 C(O)OR a21 , C(=NR e21 )NR c21 R d21 , NR c21 C(=NR e21 )NR c21 R d21 , S(O)R b21 , S(O)NR c21 R d21 , S(O) 2 R b21 , NR c21 S(O) 2 R b21 , S(O) 2 NR c21 R d21 , and are substituted with one, two, or three substituents independently selected from the oxo; R Cy2B Each C that forms 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Cycloalkyls and 4- to 10-membered heterocycloalkyls are independently unsubstituted or halogenated. 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 1～6 Haloalkyl, CN, OR a21 , SR a21 , C(O)R b21 , C(O)NR c21 R d21 , C(O)OR a21 ,OC(O)R b21 , OC(O)NR c21 R d21 , NR c21 R d21 , NR c21 C(O)R b21 , NR c21 C(O)NR c21 R d21 , NR c21 C(O)OR a21 , C(=NR e21 )NR c21 R d21 , NR c21 C(=NR e21 )NR c21 R d21 , S(O)R b21 , S(O)NR c21 R d21 , S(O) 2 R b21 , NR c21 S(O) 2 R b21 , S(O) 2 NR c21 R d21 , and are substituted with one, two, or three substituents independently selected from the oxo; H and C are independent of each other. 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 6～10 Ariel, C 3～7 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6～10 Aryl-C 1～3 Alkyl, 5-10 member heteroaryl-C 1～3 Alkyl, C 3～7 Cycloalkyl-C 1～3 Alkyl and 4- to 10-membered heterocycloalkyl-C 1～3 Selected from alkyl groups, R a21 , R b21 , R c21 , and R d21 The C that forms 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 6～10 Ariel, C 3～7 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6～10 Aryl-C 1～3 Alkyl, 5-10 member heteroaryl-C 1～3 Alkyl, C 3～7 Cycloalkyl-C 1～3 Alkyl and 4- to 10-membered heterocycloalkyl-C 1～3 Each alkyl group is C 1～6 Alkyl, Halo, CN, OR a22 , SR a22 , C(O)R b22 , C(O)NR c22 R d22 , C(O)OR a22 ,OC(O)R b22 , OC(O)NR c22 R d22 , NR c22 R d22 , NR c22 C(O)R b22 , NR c22 C(O)NR c22 R d22 , NR c22 C(O)OR a22 , C(=NR e22 )NR c22 R d22 , NR c22 C(=NR e22 )NR c22 R d22 , S(O)R b22 , S(O)NR c22 R d22 , S(O) 2 R b22 , NR c22 S(O) 2 R b22 , S(O) 2 NR c22 R d22 , and may be substituted with one, two, three, four, or five substituents independently selected from the oxo; or, R bonded to the same N atom c21 and R d21 These, together with the N atom to which they are both bonded, form a 4-membered, 5-membered, 6-membered, or 7-membered heterocycloalkyl group or a 5-membered heteroaryl group, each being C 1～6 Alkyl, Halo, CN, OR a22 , SR a22 , C(O)R b22 , C(O)NR c22 R d22 , C(O)OR a22 ,OC(O)R b22 , OC(O)NR c22 R d22 , NR c22 R d22 , NR c22 C(O)R b22 , NR c22 C(O)NR c22 R d22 , NR c22 C(O)OR a22 , C(=NR e22 )NR c22 R d22 , NR c22 C(=NR e22 )NR c22 R d22 , S(O)R b22 , S(O)NR c22 R d22 , S(O) 2 R b22 , NR c22 S(O) 2 R b22 , S(O) 2 NR c22 R d22 , and may be substituted with one, two, or three substituents independently selected from the oxo; R a22 , R b22 , R c22 , and R d22 H and C are independent of each other. 1～6 Alkyl, C 1～6 Haloalkyl, C 2～6 Alkenil, C 2～6 Alkinyl, phenyl, C 3～7 Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C 1～3 Alkyl, 5-6 member heteroaryl-C 1～3 Alkyl, C 3～7 Cycloalkyl-C 1～3 Alkyl and 4- to 7-membered heterocycloalkyl-C 1～3 Selected from alkyl groups, R a22 , R b22 , R c22 , and R d22 The C that forms 1～6 Alkyl, C 1～6 Haloalkyl, C 2～6 Alkenil, C 2～6 Alkinyl, phenyl, C 3～7 Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C 1～3 Alkyl, 5-6 member heteroaryl-C 1～3 Alkyl, C 3～7 Cycloalkyl-C 1～3 Alkyl and 4- to 7-membered heterocycloalkyl-C 1～3 Alkyl compounds are OH, CN, amino, and NH(C) respectively. 1～6 Alkyl), N(C 1～6 Alkyl) 2 Hello, C 1～6 Alkyl, C 1～6 Alkoxy, C 1～6 Haloalkyl, C 1～6 It may be substituted with one, two, or three substituents independently selected from haloalkoxys and oxos; or, R bonded to the same N atom c22 and R d22 These, together with the N atom to which they are both bonded, form a 4-membered, 5-membered, 6-membered, or 7-membered heterocycloalkyl group or a 5-membered heteroaryl group, each of which is either unsubstituted or OH, CN, amino, or NH(C) 1～6 Alkyl), N(C 1～6 Alkyl) 2 Hello, C 1～6 Alkyl, C 1～6 Alkoxy, C 1～6 Haloalkyl, C 1～6 Substituted with one, two, or three substituents independently selected from haloalkoxys and oxos; R e21 and R e22 These are H, CN, or NO, respectively, independently. 2 That is the case.

157. Cy 2A The compound or salt thereof according to claim 156, wherein is unsubstituted or substituted aryl.

158. Cy 2A The compound or salt thereof according to claim 157, wherein is an unsubstituted or substituted phenyl.

159. Cy 2A The compound or a salt thereof according to claim 158, wherein is a substituted phenyl.

160. Cy 2A at least one OR a21 or at least one C(=NR) e21 )NR c21 R d21 , C(=NOR a21 )NR c21 R d21 , C(=NOC(O)R b21 )NR c21 R d21 , or C(=NR e21 )NR c21 C(O)OR a21 A compound or salt thereof according to any one of claims 156 to 159, which is substituted with

161. Cy 2A at least one OR a21 It is replaced with and C 1～6 Alkyl, C 1～6 A compound or salt thereof according to any one of claims 156 to 160, substituted with at least one further substituent selected from the group consisting of haloalkyls and halogens.

162. Cy 2A It is substituted with at least one OH group, and C 1～6 Alkyl, C 1～6 A compound or salt thereof according to any one of claims 156 to 161, substituted with at least one further substituent selected from the group consisting of haloalkyls and halogens.

163. Cy 2A Preferably at position 4, at least one C(=NR e21 )NR c21 R d21 , C(=NOR a21 )NR c21 R d21 , C(=NOC(O)R b21 )NR c21 R d21 , C(=NR e21 )NR c21 C(O)OR a21 A compound or salt thereof according to any one of claims 156 to 162, which is substituted with

164. Cy 2A Preferably at position 4, at least one C(=NR e21 )NR c21 R d21 A compound or salt thereof according to claim 163, which is substituted with [the compound or salt of the of the claim 163, which is substituted with [the compound or salt of the compound or salt of the compound].

165. Cy 2A Preferably at position 4, at least one C(=NH)NH 2 A compound or salt thereof according to claim 164, which is substituted with [the compound or salt of the

166. Cy 2A The formula is as follows: The compound or salt thereof according to claim 159, which is any one of the above.

167. Cy 2A In the formula defining R, Cy2A C 1～6 The compound or a salt thereof according to claim 166, wherein the compound is alkyl, for example methyl, or halogen, for example Cl or Br, or amino.

168. Cy 2A The formula is as follows: The compound or salt thereof according to claim 159, which is any one of the above.

169. R a21 C 1～6 It is alkyl, R b21 C 1～6 The compound or a salt thereof according to claim 168, wherein the compound is alkyl.

170. Cy 2A The compound or salt thereof according to claim 156, wherein is an unsubstituted or substituted heteroaryl, for example pyridine-3-yl, 1H-pyrrolo[2,3-b]pyridine-5-yl, or 1H-benzo[d]imidazole-6-yl.

171. Cy 2A The formula is as follows: The compound or salt thereof according to claim 170, which is any one of the following.

172. Cy 2A Each R in the formula defining Cy2A C 1～6 The compound or a salt thereof according to claim 171, wherein the compound is an alkyl group, for example methyl or ethyl, preferably methyl, or a halogen, for example F, Cl, or Br, preferably Cl.

173. Cy 2A Each R bonded to nitrogen in the formula defining the Cy2A C 1～6 The compound or a salt thereof according to claim 171 or 172, wherein the compound is alkyl, for example, methyl or ethyl.

174. R 21 C 1～6 A compound or salt thereof according to any one of claims 156 to 173, wherein the compound is alkyl.

175. R 21 The compound or a salt thereof according to claim 174, wherein is methyl.

176. R 21 A compound or salt thereof according to any one of claims 156 to 173, wherein is H.

177. R 22 A compound or salt thereof according to any one of claims 156 to 176, wherein is H.

178. R 22 C 1～6 A compound or salt thereof according to any one of claims 156 to 176, wherein the compound is alkyl.

179. R 22 The compound or a salt thereof according to claim 178, wherein is methyl.

180. R 21 and R 22 The compound or salt thereof according to any one of claims 156 to 179, wherein they, together with the groups to which they are bonded, form a 4-6 membered heterocycloalkyl ring.

181. A compound or salt thereof according to any one of claims 156 to 180, having formula (IIA).

182. The following formula (IIA-1a) or (IIA-1b): A compound or salt thereof according to claim 181, which matches any of the following.

183. The following equations (IIA-2) to (IIA-5): A compound or salt thereof according to any one of claims 181 or 182, which matches any one of the above.

184. The following equations (IIA-2a) to (IIA-5b): A compound or salt thereof according to claim 183, which matches any of the following.

185. A compound or salt thereof according to any one of claims 156 to 180, which is formula (IIB).

186. The following formula (IIB-1a) or (IIB-1b): A compound or salt thereof according to claim 185, which matches any of the following.

187. R 23 A compound or salt thereof according to any one of claims 156 to 184, wherein is H.

188. R 23 C 1～6 A compound or salt thereof according to any one of claims 156 to 184, wherein the compound is alkyl.

189. R 24 A compound or salt thereof according to any one of claims 156 to 188, wherein is H.

190. R 24 C 1～6 A compound or salt thereof according to any one of claims 156 to 188, wherein the compound is alkyl.

191. R 24 A compound or salt thereof according to any one of claims 156 to 188, wherein is phenyl.

192. R 25 Cy 2B The compound or salt thereof according to any one of claims 156 to 191.

193. R 25 (C 1～6 Alkilen)Cy 2B , (C 2～6 Alkenylene) Cy 2B , or (C 2～6 Alkinylene)Cy 2B And R 25 C 1～6 Alkylene, C 2～6 Alkenylene, or C 2～6 A compound or salt thereof according to any one of claims 156 to 191, wherein the alkynylene component is either unsubstituted or substituted.

194. R 25 (C 1～6 Alkilen)Cy 2B , (C 2～6 Alkenylene) Cy 2B , or (C 2～6 Alkinylene)Cy 2B And R 25 C 1～6 Alkylene, C 2～6 Alkenylene, or C 2～6 A compound or salt thereof according to any one of claims 156 to 193, wherein the alkynylene component is not substituted.

195. R 25 (CR 25A R 25B ) n25 Cy 2B The compound or salt thereof according to any one of claims 156 to 194.

196. Each R 25A The compound or a salt thereof according to claim 195, wherein is H.

197. Each R 25B The compound or salt thereof according to claim 194 or 195, wherein is H.

198. A compound or salt thereof according to any one of claims 194 to 196, wherein n25 is 0.

199. A compound or salt thereof according to any one of claims 194 to 196, wherein n25 is 1.

200. A compound or salt thereof according to any one of claims 194 to 196, wherein n25 is 2.

201. R 25 CH 2 Cy 2B The compound or salt thereof according to any one of claims 194 to 196.

202. R 25 CH 2 CH 2 Cy 2B The compound or salt thereof according to any one of claims 194 to 196.

203. Cy 2B is non-substituted C 6～10 A compound or salt thereof according to any one of claims 156 to 202, wherein the compound is an aryl compound.

204. Cy 2B The compound or a salt thereof according to claim 203, wherein is an unsubstituted phenyl.

205. Cy 2B The compound or salt thereof according to claim 203, wherein is an unsubstituted naphthyl, for example, 1-naphthyl or 2-naphthyl.

206. Cy 2B A compound or salt thereof according to any one of claims 156 to 202, wherein is an unsubstituted 5- to 10-membered heteroaryl compound.

207. Cy 2B The compound or salt thereof according to claim 206, wherein is an unsubstituted pyridyl, for example, an unsubstituted 2-, 3-, or 4-pyridyl, or an unsubstituted quinolyl, for example, an unsubstituted 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl.

208. Cy 2B Substitution C 6～10 A compound or salt thereof according to any one of claims 156 to 202, wherein the compound is an aryl compound.

209. Cy 2B The compound or a salt thereof according to claim 208, wherein is a substituted phenyl.

210. Cy 2B The compound or salt thereof according to claim 209, wherein is biphenylyl (i.e., phenyl-substituted phenyl), for example, 2-, 3-, or 4-biphenylyl.

211. Cy 2B The compound or salt thereof according to claim 208, wherein is a substituted naphthyl, for example, 1-naphthyl or 2-naphthyl.

212. Cy 2B A compound or salt thereof according to any one of claims 156 to 202, wherein is a substituted 5- to 10-membered heteroaryl compound.

213. Cy 2B The compound or salt thereof according to claim 212, wherein is a substituted pyridyl, for example, a substituted 2-, 3-, or 4-pyridyl, or a substituted quinolyl, for example, a substituted 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl.

214. Cy 2B However, R Cy2B , halogen, and C 1～6 Each R is substituted with one, two, three, four, or five substituents independently selected from the haloalkyl groups; Cy2B C 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl and C 6～10 Selected from aryl or 5- to 10-membered heteroaryl, R Cy2B Each C that forms 6～10 Aryl or 5- to 10-membered heteroaryl compounds, either unsubstituted or halogenated, C 1～6 Alkyl, C 2～6 Alkenil, C 2～6 A compound or salt thereof according to any one of claims 208 to 213, substituted with one, two, or three substituents independently selected from alkynyl and haloalkyl groups.

215. R 25 The formula is as follows: A compound or salt thereof according to any one of claims 156 to 214, selected from the groups of the following.

216. R 25 R in the expression representing Cy2B C 1～6 The compound or salt thereof according to claim 215, wherein the alkyl group is, for example, methyl or ethyl, preferably methyl, or the halogen group is, for example, fluorine or chlorine, preferably fluorine.

217. R 25 R in the expression representing Cy2B C 1～6 The compound or a salt thereof according to claim 215, wherein the compound is alkyl, for example, methyl or ethyl, preferably methyl.

218. R 25 R in the expression representing Cy2B The compound or salt thereof according to claim 215, wherein is a halogen, for example, fluorine or chlorine, preferably fluorine.

219. R a21 , R b21 , R c21 , R d21 , R a22 , R b22 , R c22 , R d22 H and C are independent of each other. 1～6 A compound or salt thereof according to any one of claims 156 to 218, selected from alkyl groups.

220. Each R e21 and each R e22 A compound or salt thereof according to any one of claims 156 to 219, wherein is H.

221. A pharmaceutical composition comprising a compound according to any one of claims 156 to 220 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

222. Compounds of formula (III) or salts thereof for use in the treatment of MASP-2 related diseases or disorders: During the ceremony, Cy 3A is either non-substituted or substituted C 6～10 It is an aryl or unsubstituted or substituted 5- to 10-membered heteroaryl; Cy 3A The ring atoms of the 5-10 membered heteroaryl that form the Cy 3A Substitution C that forms 6～10 Aryl or substituted 5-10 member heteroaryls are R Cy3A , halogen, C 1～6 Haloalkyl, CN, OR a31 , SR a31 , C(O)R b31 , C(O)NR c31 R d31 , C(O)OR a31 ,OC(O)R b31 , OC(O)NR c31 R d31 , NR c31 R d31 , NR c31 C(O)R b31 , NR c31 C(O)NR c31 R d31 , NR c31 C(O)OR a31 , C(=NR e31 )NR c31 R d31 , C(=NOR a31 )NR c31 R d31 , C(=NOC(O)R b31 )NR c31 R d31 , C(=NR e31 )NR c31 C(O)OR a31 , NR c31 C(=NR e31 )NR c31 R d31 , S(O)R b31 , S(O)NR c31 R d31 , S(O) 2 R b31 , NR c31 S(O) 2 R b31 , S(O) 2 NR c31 R d31 Substituted with one, two, three, four, or five substituents independently selected from the , and oxo; Each R Cy3A C is independent 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Selected from cycloalkyl and 4- to 10-membered heterocycloalkyl groups, R Cy3A The ring atoms of the 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl groups that form the ring consist of one, two, three, or four heteroatoms selected from carbon atoms and O, N, and S, R Cy3A Each C that forms 1～6 Alkyl, C 2～6 Alkenyl, or C 2～6 Alkynnyls are independently unsubstituted or halogen, CN, OR a31 , SR a31 , C(O)R b31 , C(O)NR c31 R d31 , C(O)OR a31 ,OC(O)R b31 , OC(O)NR c31 R d31 , NR c31 R d31 , NR c31 C(O)R b31 , NR c31 C(O)NR c31 R d31 , NR c31 C(O)OR a31 , C(=NR e31 )NR c31 R d31 , NR c31 C(=NR e31 )NR c31 R d31 , S(O)R b31 , S(O)NR c31 R d31 , S(O) 2 R b31 , NR c31 S(O) 2 R b31 , S(O) 2 NR c31 R d31 , and are substituted with one, two, or three substituents independently selected from the oxo, R Cy3A Each C that forms 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Cycloalkyls and 4- to 10-membered heterocycloalkyls are independently unsubstituted or halogenated. 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 1～6 Haloalkyl, CN, OR a31 , SR a31 , C(O)R b31 , C(O)NR c31 R d31 , C(O)OR a31 ,OC(O)R b31 , OC(O)NR c31 R d31 , NR c31 R d31 , NR c31 C(O)R b31 , NR c31 C(O)NR c31 R d31 , NR c31 C(O)OR a31 , C(=NR e31 )NR c31 R d31 , NR c31 C(=NR e31 )NR c31 R d31 , S(O)R b31 , S(O)NR c31 R d31 , S(O) 2 R b31 , NR c31 S(O) 2 R b31 , S(O) 2 NR c31 R d31 , and are substituted with one, two, or three substituents independently selected from the oxo; R 31 is H, or C 1～6 Alkyl, C 6～10 Aryl-C 1～6 Alkyl or 5-10 member heteroaryl-C 1～6 It is alkyl, R 31 C that forms 1～6 Alkyls are either unsubstituted or contain halogens, CN, OR a31 , SR a31 , C(O)R b31 , C(O)NR c31 R d31 , C(O)OR a31 ,OC(O)R b31 , OC(O)NR c31 R d31 , NR c31 R d31 , NR c31 C(O)R b31 , NR c31 C(O)NR c31 R d31 , NR c31 C(O)OR a31 , C(=NR e31 )NR c31 R d31 , NR c31 C(=NR e31 )NR c31 R d31 , S(O)R b31 , S(O)NR c31 R d31 , S(O) 2 R b31 , NR c31 S(O) 2 R b31 , S(O) 2 NR c31 R d31 , and are substituted with one, two, or three substituents independently selected from the oxo, R 31 C that forms 6～10 Aryl-C 1～6 Alkyl or 5-10 member heteroaryl-C 1～6 Alkyl is either unsubstituted or C 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 1～6 Haloalkyl, CN, OR a31 , SR a31 , C(O)R b31 , C(O)NR c31 R d31 , C(O)OR a31 ,OC(O)R b31 , OC(O)NR c31 R d31 , NR c31 R d31 , NR c31 C(O)R b31 , NR c31 C(O)NR c31 R d31 , NR c31 C(O)OR a31 , C(=NR e31 )NR c31 R d31 , NR c31 C(=NR e31 )NR c31 R d31 , S(O)R b31 , S(O)NR c31 R d31 , S(O) 2 R b31 , NR c31 S(O) 2 R b31 , S(O) 2 NR c31 R d31 , and are substituted with one, two, or three substituents independently selected from the oxo; R 32 is H or C 1～6 It is alkyl; or, R 31 and R 32 These, together with the groups to which they are bonded, form a 4- to 6-membered heterocycloalkyl ring; R 33 is Cy 3B , (CR 33A R 33B ) n33 Cy 3B , (C 1～6 Alkilen)Cy 3B , (C 2～6 Alkenylene) Cy 3B , or (C 2～6 Alkinylene)Cy 3B And R 35 C 1～6 Alkylene, C 2～6 Alkenylene, or C 2～6 The alkylylene component is either unsubstituted or contains halogen, CN, OR a31 , SR a31 , C(O)R b31 , C(O)NR c31 R d31 , C(O)OR a31 ,OC(O)R b31 , OC(O)NR c31 R d31 , NR c31 R d31 , NR c31 C(O)R b31 , NR c31 C(O)NR c31 R d31 , NR c31 C(O)OR a31 , C(=NR e31 )NR c31 R d31 , NR c31 C(=NR e31 )NR c31 R d31 , S(O)R b31 , S(O)NR c31 R d31 , S(O) 2 R b31 , NR c31 S(O) 2 R b31 , S(O) 2 NR c31 R d31 Substituting with one, two, three, four, or five substituents independently selected from the group consisting of , and oxo; Each R 33A H or C 1～6 It is alkyl; Each R 33B H or C 1～6 It is alkyl; or, R bonded to the same carbon atom 33A and R 33B is any other R 33A base and R 33B Originally independent, then together - (CH 2 ) 2～5 - may be formed, thereby forming a 3- to 6-membered cycloalkyl ring; n33 is 0, 1, 2, or 3; Cy 3B is either non-substituted or substituted C 6～10 Aryl, unsubstituted or substituted 5- to 10-membered heteroaryl, unsubstituted or substituted C 3～10 Cycloalkyl, or unsubstituted or substituted 4- to 10-membered heterocycloalkyl; Cy 3B The ring atoms of the 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl groups that form the ring consist of one, two, or three heteroatoms selected from carbon atoms and O, N, and S; Cy 3B Substitution C that forms 6～10 Aryl, substituted 5-10 member heteroaryl, substituted C 3～10 Cycloalkyls, or substituted 4- to 10-membered heterocycloalkyls, R Cy3B , halogen, C 1～6 Haloalkyl, CN, OR a31 , SR a31 , C(O)R b31 , C(O)NR c31 R d31 , C(O)OR a31 ,OC(O)R b31 , OC(O)NR c31 R d31 , NR c31 R d31 , NR c31 C(O)R b31 , NR c31 C(O)NR c31 R d31 , NR c31 C(O)OR a31 , C(=NR e31 )NR c31 R d31 , C(=NOR a31 )NR c31 R d31 , C(=NOC(O)R b31 )NR c31 R d31 , C(=NR e31 )NR c31 C(O)OR a31 , NR c31 C(=NR e31 )NR c31 R d31 , S(O)R b31 , S(O)NR c31 R d31 , S(O) 2 R b31 , NR c31 S(O) 2 R b31 , S(O) 2 NR c31 R d31 Substituted with one, two, three, four, or five substituents independently selected from the , and oxo; Each R Cy3B C is independent 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Selected from cycloalkyl and 4- to 10-membered heterocycloalkyl groups, R Cy3B The ring atoms of the 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl groups that form the ring consist of one, two, or three heteroatoms selected from carbon atoms and O, N, and S; R Cy3B Each C that forms 1～6 Alkyl, C 2～6 Alkenyl, or C 2～6 Alkynnyls are independently unsubstituted or halogen, CN, OR a31 , SR a31 , C(O)R b31 , C(O)NR c31 R d31 , C(O)OR a31 ,OC(O)R b31 , OC(O)NR c31 R d31 , NR c31 R d31 , NR c31 C(O)R b31 , NR c31 C(O)NR c31 R d31 , NR c31 C(O)OR a31 , C(=NR e31 )NR c31 R d31 , NR c31 C(=NR e31 )NR c31 R d31 , S(O)R b31 , S(O)NR c31 R d31 , S(O) 2 R b31 , NR c31 S(O) 2 R b31 , S(O) 2 NR c31 R d31 , and are substituted with one, two, or three substituents independently selected from the oxo; R Cy3B Each C that forms 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Cycloalkyls and 4- to 10-membered heterocycloalkyls are independently unsubstituted or halogenated. 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 1～6 Haloalkyl, CN, OR a31 , SR a31 , C(O)R b31 , C(O)NR c31 R d31 , C(O)OR a31 ,OC(O)R b31 , OC(O)NR c31 R d31 , NR c31 R d31 , NR c31 C(O)R b31 , NR c31 C(O)NR c31 R d31 , NR c31 C(O)OR a31 , C(=NR e31 )NR c31 R d31 , NR c31 C(=NR e31 )NR c31 R d31 , S(O)R b31 , S(O)NR c31 R d31 , S(O) 2 R b31 , NR c31 S(O) 2 R b31 , S(O) 2 NR c31 R d31 , and are substituted with one, two, or three substituents independently selected from the oxo; R 34 H and C 1～6 Selected from alkyl groups; R 35 is H, unsubstituted or substituted C 1～6 Alkyl, and Cy 3C More selected, R 35 Substitution C that forms 1～6 Alkyl is Cy 3C , halogen, CN, OR a31 , SR a31 , C(O)R b31 , C(O)NR c31 R d31 , C(O)OR a31 ,OC(O)R b31 , OC(O)NR c31 R d31 , NR c31 R d31 , NR c31 C(O)R b31 , NR c31 C(O)NR c31 R d31 , NR c31 C(O)OR a31 , C(=NR e31 )NR c31 R d31 , NR c31 C(=NR e31 )NR c31 R d31 , S(O)R b31 , S(O)NR c31 R d31 , S(O) 2 R b31 , NR c31 S(O) 2 R b31 , S(O) 2 NR c31 R d31 It is substituted with one, two, three, four, or five substituents selected from the group consisting of , and oxo; however, R 35 One or fewer of the substituents are Cy 3C and; Cy 3C is either non-substituted or substituted C 6～10 Aryl, unsubstituted or substituted 5- to 10-membered heteroaryl, unsubstituted or substituted C 3～10 Cycloalkyl, or unsubstituted or substituted 4- to 10-membered heterocycloalkyl; Cy 3C The ring atoms of the 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl groups that form the ring consist of one, two, or three heteroatoms selected from carbon atoms and O, N, and S; Cy 3C Substitution C that forms 6～10 Aryl, substituted 5-10 member heteroaryl, substituted C 3～10 Cycloalkyls, or substituted 4- to 10-membered heterocycloalkyls, R Cy3C , halogen, C 1～6 Haloalkyl, CN, OR a31 , SR a31 , C(O)R b31 , C(O)NR c31 R d31 , C(O)OR a31 ,OC(O)R b31 , OC(O)NR c31 R d31 , NR c31 R d31 , NR c31 C(O)R b31 , NR c31 C(O)NR c31 R d31 , NR c31 C(O)OR a31 , C(=NR e31 )NR c31 R d31 , C(=NOR a31 )NR c31 R d31 , C(=NOC(O)R b31 )NR c31 R d31 , C(=NR e31 )NR c31 C(O)OR a31 , NR c31 C(=NR e31 )NR c31 R d31 , S(O)R b31 , S(O)NR c31 R d31 , S(O) 2 R b31 , NR c31 S(O) 2 R b31 , S(O) 2 NR c31 R d31 Substituted with one, two, three, four, or five substituents independently selected from the , and oxo; Each R Cy3C C is independent 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Selected from cycloalkyl and 4- to 10-membered heterocycloalkyl groups, R Cy3C The ring atoms of the 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl groups that form the ring consist of one, two, or three heteroatoms selected from carbon atoms and O, N, and S; R Cy3C Each C that forms 1～6 Alkyl, C 2～6 Alkenyl, or C 2～6 Alkynnyls are independently unsubstituted or halogen, CN, OR a31 , SR a31 , C(O)R b31 , C(O)NR c31 R d31 , C(O)OR a31 ,OC(O)R b31 , OC(O)NR c31 R d31 , NR c31 R d31 , NR c31 C(O)R b31 , NR c31 C(O)NR c31 R d31 , NR c31 C(O)OR a31 , C(=NR e31 )NR c31 R d31 , NR c31 C(=NR e31 )NR c31 R d31 , S(O)R b31 , S(O)NR c31 R d31 , S(O) 2 R b31 , NR c31 S(O) 2 R b31 , S(O) 2 NR c31 R d31 , and are substituted with one, two, or three substituents independently selected from the oxo; R Cy3C Each C that forms 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Cycloalkyls and 4- to 10-membered heterocycloalkyls are independently unsubstituted or halogenated. 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 1～6 Haloalkyl, CN, OR a31 , SR a31 , C(O)R b31 , C(O)NR c31 R d31 , C(O)OR a31 ,OC(O)R b31 , OC(O)NR c31 R d31 , NR c31 R d31 , NR c31 C(O)R b31 , NR c31 C(O)NR c31 R d31 , NR c31 C(O)OR a31 , C(=NR e31 )NR c31 R d31 , NR c31 C(=NR e31 )NR c31 R d31 , S(O)R b31 , S(O)NR c31 R d31 , S(O) 2 R b31 , NR c31 S(O) 2 R b31 , S(O) 2 NR c31 R d31 , and are substituted with one, two, or three substituents independently selected from the oxo; R 36 H and C 1～6 Selected from alkyl groups; R a31 , R b31 , R c31 , and R d31 H and C are independent of each other. 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 6～10 Ariel, C 3～7 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6～10 Aryl-C 1～3 Alkyl, 5-10 member heteroaryl-C 1～3 Alkyl, C 3～7 Cycloalkyl-C 1～3 Alkyl and 4- to 10-membered heterocycloalkyl-C 1～3 Selected from alkyl groups, R a31 , R b31 , R c31 , and R d31 The C that forms 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 6～10 Ariel, C 3～7 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6～10 Aryl-C 1～3 Alkyl, 5-10 member heteroaryl-C 1～3 Alkyl, C 3～7 Cycloalkyl-C 1～3 Alkyl and 4- to 10-membered heterocycloalkyl-C 1～3 Each alkyl group is C 1～6 Alkyl, Halo, CN, OR a32 , SR a32 , C(O)R b32 , C(O)NR c32 R d32 , C(O)OR a32 ,OC(O)R b32 , OC(O)NR c32 R d32 , NR c32 R d32 , NR c32 C(O)R b32 , NR c32 C(O)NR c32 R d32 , NR c32 C(O)OR a32 , C(=NR e32 )NR c32 R d32 , NR c32 C(=NR e32 )NR c32 R d32 , S(O)R b32 , S(O)NR c32 R d32 , S(O) 2 R b32 , NR c32 S(O) 2 R b32 , S(O) 2 NR c32 R d32 , and may be substituted with one, two, three, four, or five substituents independently selected from the oxo; or, R bonded to the same N atom c31 and R d31 These, together with the N atom to which they are both bonded, form a 4-membered, 5-membered, 6-membered, or 7-membered heterocycloalkyl group or a 5-membered heteroaryl group, each being C 1～6 Alkyl, Halo, CN, OR a32 , SR a32 , C(O)R b32 , C(O)NR c32 R d32 , C(O)OR a32 ,OC(O)R b32 , OC(O)NR c32 R d32 , NR c32 R d32 , NR c32 C(O)R b32 , NR c32 C(O)NR c32 R d32 , NR c32 C(O)OR a32 , C(=NR e32 )NR c32 R d32 , NR c32 C(=NR e32 )NR c32 R d32 , S(O)R b32 , S(O)NR c32 R d32 , S(O) 2 R b32 , NR c32 S(O) 2 R b32 , S(O) 2 NR c32 R d32 , and may be substituted with one, two, or three substituents independently selected from the oxo; R a32 , R b32 , R c32 , and R d32 H and C are independent of each other. 1～6 Alkyl, C 1～6 Haloalkyl, C 2～6 Alkenil, C 2～6 Alkinyl, phenyl, C 3～7 Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C 1～3 Alkyl, 5-6 member heteroaryl-C 1～3 Alkyl, C 3～7 Cycloalkyl-C 1～3 Alkyl and 4- to 7-membered heterocycloalkyl-C 1～3 Selected from alkyl groups, R a32 , R b32 , R c32 , and R d32 The C that forms 1～6 Alkyl, C 1～6 Haloalkyl, C 2～6 Alkenil, C 2～6 Alkinyl, phenyl, C 3～7 Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C 1～3 Alkyl, 5-6 member heteroaryl-C 1～3 Alkyl, C 3～7 Cycloalkyl-C 1～3 Alkyl and 4- to 7-membered heterocycloalkyl-C 1～3 Alkyl compounds are OH, CN, amino, and NH(C) respectively. 1～6 Alkyl), N(C 1～6 Alkyl) 2 Hello, C 1～6 Alkyl, C 1～6 Alkoxy, C 1～6 Haloalkyl, C 1～6 It may be substituted with one, two, or three substituents independently selected from haloalkoxys and oxos; or, R bonded to the same N atom c32 and R d32 These, together with the N atom to which they are both bonded, form a 4-membered, 5-membered, 6-membered, or 7-membered heterocycloalkyl group or a 5-membered heteroaryl group, each of which is either unsubstituted or OH, CN, amino, or NH(C) 1～6 Alkyl), N(C 1～6 Alkyl) 2 Hello, C 1～6 Alkyl, C 1～6 Alkoxy, C 1～6 Haloalkyl, C 1～6 Substituted with one, two, or three substituents independently selected from haloalkoxys and oxos; R e31 and R e32 These are H, CN, or NO, respectively, independently. 2 That is the case.

223. Cy 3A The compound or salt thereof according to claim 222, wherein is unsubstituted or substituted aryl.

224. Cy 3A The compound or salt thereof according to claim 223, wherein is an unsubstituted or substituted phenyl.

225. Cy 3A The compound or a salt thereof according to claim 224, wherein is a substituted phenyl.

226. Cy 3A at least one OR a31 or at least one C(=NR) e31 )NR c31 R d31 , C(=NOR a31 )NR c31 R d31 , C(=NOC(O)R b31 )NR c31 R d31 , or C(=NR e31 )NR c31 C(O)OR a31 A compound or salt thereof according to any one of claims 222 to 225, which is substituted with

227. Cy 3A at least one OR a31 It is replaced with and C 1～6 Alkyl, C 1～6 A compound or salt thereof according to any one of claims 222 to 226, substituted with at least one further substituent selected from the group consisting of haloalkyls and halogens.

228. Cy 3A It is substituted with at least one OH group, and C 1～6 Alkyl, C 1～6 A compound or salt thereof according to any one of claims 222 to 227, substituted with at least one further substituent selected from the group consisting of haloalkyls and halogens.

229. Cy 3A Preferably at position 4, at least one C(=NR e31 )NR c31 R d31 , C(=NOR a31 )NR c31 R d31 , C(=NOC(O)R b31 )NR c31 R d31 , C(=NR e31 )NR c31 C(O)OR a31 A compound or salt thereof according to any one of claims 222 to 228, which is substituted with

230. Cy 3A Preferably at position 4, at least one C(=NR e31 )NR c31 R d31 A compound or salt thereof according to claim 229, which is substituted with [the compound or salt of the of the compound or salt of the compound of the compound or salt of the compound of the compound or salt of the compound of the compound or salt of the

231. Cy 3A Preferably at position 4, at least one C(=NH)NH 2 A compound or salt thereof according to claim 230, which is substituted with [the compound or salt of the of the claim 230, which is substituted with [the compound or salt of the compound or salt of the compound].

232. Cy 3A The formula is as follows: The compound or salt thereof according to claim 225, which is any one of the above.

233. Cy 3A The formula is as follows: The compound or salt thereof according to claim 225, which is any one of the above.

234. Cy 3A In the formula defining R a31 C 1～6 Alkyl, for example, methyl; R b31 C 1～6 Alkyl, for example, methyl, or R b31 C 1～6 Haloalkyls, for example, trifluoromethyl; R c31 The compound or a salt thereof according to claim 233, wherein is alkyl, for example, methyl.

235. Cy 3A The compound or salt thereof according to claim 222, wherein is unsubstituted or substituted heteroaryl.

236. Cy 3A The compound or salt thereof according to claim 235, wherein is unsubstituted or substituted pyridine-3-yl, 1H-pyrrolo[2,3-b]pyridine-5-yl, or 1H-benzo[d]imidazole-6-yl.

237. Cy 3A The formula is as follows: A compound or salt thereof according to claim 234 or 235, which is any one of the above.

238. Cy 3A Each R in the formula defining Cy3A C 1～6 The compound or salt thereof according to claim 237, wherein the compound is an alkyl group, for example methyl or ethyl, preferably methyl, or a halogen, for example F, Cl, or Br, preferably Cl, or amino.

239. Cy 3A Each R bonded to nitrogen in the formula defining the Cy3A C 1～6 The compound or a salt thereof according to claim 237 or 238, wherein the compound is alkyl, for example, methyl or ethyl.

240. R 31 C 1～6 A compound or salt thereof according to any one of claims 222 to 239, wherein the compound is alkyl.

241. R 31 The compound or a salt thereof according to claim 240, wherein is methyl.

242. R 31 A compound or salt thereof according to any one of claims 222 to 241, wherein is H.

243. R 32 A compound or salt thereof according to any one of claims 222 to 242, wherein is H.

244. R 32 C 1～6 A compound or salt thereof according to any one of claims 222 to 242, wherein the compound is alkyl.

245. R 32 The compound or a salt thereof according to claim 244, wherein is methyl.

246. R 31 and R 32 The compound or salt thereof according to any one of claims 222 to 239, wherein they, together with the groups to which they are bonded, form a 4-6 membered heterocycloalkyl ring.

247. The following equations (III-1a) to (III-1h): A compound or salt thereof according to any one of claims 222 to 246, which matches any one of the above.

248. R 33 Cy 3B The compound or salt thereof according to any one of claims 222 to 247.

249. R 33 (C 1～6 Alkilen)Cy 3B , (C 2～6 Alkenylene) Cy 3B , or (C 2～6 Alkinylene)Cy 3B And R 35 C 1～6 Alkylene, C 2～6 Alkenylene, or C 2～6 A compound or salt thereof according to any one of claims 222 to 247, wherein the alkynylene component is not substituted.

250. R 33 (C 1～6 Alkilen)Cy 3B , (C 2～6 Alkenylene) Cy 3B , or (C 2～6 Alkinylene)Cy 3B And R 35 C 1～6 Alkylene, C 2～6 Alkenylene, or C 2～6 Alkinylene component is halogen, CN, OR a31 , SR a31 , C(O)R b31 , C(O)NR c31 R d31 , C(O)OR a31 ,OC(O)R b31 , OC(O)NR c31 R d31 , NR c31 R d31 , NR c31 C(O)R b31 , NR c31 C(O)NR c31 R d31 , NR c31 C(O)OR a31 , C(=NR e31 )NR c31 R d31 , NR c31 C(=NR e31 )NR c31 R d31 , S(O)R b31 , S(O)NR c31 R d31 , S(O) 2 R b31 , NR c31 S(O) 2 R b31 , S(O) 2 NR c31 R d31 A compound or salt thereof according to any one of claims 222 to 249, substituted with one, two, three, four, or five substituents independently selected from the group consisting of , and oxo.

251. R 33 (CR 33A R 33B ) n33 Cy 3B The compound or salt thereof according to any one of claims 222 to 247.

252. Each R 33A The compound or a salt thereof according to claim 251, wherein is H.

253. Each R 33B The compound or salt thereof according to claim 251 or 252, wherein is H.

254. A compound or salt thereof according to any one of claims 251 to 253, wherein n33 is 0.

255. A compound or salt thereof according to any one of claims 251 to 253, wherein n33 is 1.

256. A compound or salt thereof according to any one of claims 251 to 253, wherein n33 is 2.

257. A compound or salt thereof according to any one of claims 251 to 253, wherein n33 is 3.

258. R 33 CH 2 Cy 3B The compound or salt thereof according to any one of claims 222 to 247.

259. R 33 CH 2 CH 2 Cy 3B The compound or salt thereof according to any one of claims 222 to 247.

260. The following equations (III-2) to (III-4): A compound or salt thereof according to claim 259, which matches any of the following.

261. The following equations (III-2a) to (III-2h): A compound or salt thereof according to claim 260, which matches any of the following.

262. The following equations (III-3a) to (III-3h): A compound or salt thereof according to claim 260, which matches any of the following.

263. The following equations (III-4a) to (III-4h): A compound or salt thereof according to claim 260, which matches any of the following.

264. R 33 CH 2 CH 2 CH 2 Cy 3B The compound or salt thereof according to any one of claims 222 to 247.

265. Cy 3B is non-substituted C 6～10 A compound or salt thereof according to any one of claims 222 to 264, wherein the compound is aryl.

266. Cy 3B The compound or a salt thereof according to claim 265, wherein is an unsubstituted phenyl.

267. R 33 CH 2 CH 2 The compound or a salt thereof according to claim 266, wherein the pH is [value].

268. Cy 3B The compound or salt thereof according to claim 266, wherein is an unsubstituted naphthyl, for example, 1-naphthyl or 2-naphthyl.

269. R 33 CH 2 CH 2 -1-Naphthyl or CH 2 CH 2 The compound or a salt thereof according to claim 268, wherein the compound is -2-naphthyl.

270. Cy 3B A compound or salt thereof according to any one of claims 222 to 264, wherein is an unsubstituted 5- to 10-membered heteroaryl compound.

271. Cy 3B The compound or salt thereof according to claim 270, wherein is an unsubstituted pyridyl, for example, unsubstituted 2-, 3-, or 4-pyridyl; an unsubstituted quinolyl, for example, unsubstituted 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl; an unsubstituted benzo[b]thiophenyl, for example, unsubstituted 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thiophenyl; or an unsubstituted indolyl, for example, unsubstituted indole-2-yl, -3-yl, -4-yl, -5-yl, -6-yl, or -7-yl.

272. Cy 3B is non-substituted C 3～10 A compound or salt thereof according to any one of claims 222 to 264, wherein the compound is a cycloalkyl compound.

273. Cy 3B The compound or salt thereof according to claim 272, wherein is unsubstituted cyclopentyl, cyclohexyl, or cycloheptyl.

274. Cy 3B A compound or salt thereof according to any one of claims 222 to 264, wherein is an unsubstituted 4 to 10-membered heterocycloalkyl group.

275. Cy 3B Substitution C 6～10 A compound or salt thereof according to any one of claims 222 to 264, wherein the compound is aryl.

276. Cy 3B The compound or a salt thereof according to claim 275, wherein is a substituted phenyl.

277. Cy 3B The compound or salt thereof according to claim 275, wherein is a substituted naphthyl, for example, 1-naphthyl or 2-naphthyl.

278. Cy 3B A compound or salt thereof according to any one of claims 222 to 264, wherein is a substituted 5- to 10-membered heteroaryl compound.

279. Cy 3B The compound or salt thereof according to claim 278, wherein is a substituted pyridyl, for example, a substituted 2-, 3-, or 4-pyridyl; a substituted quinolyl, for example, a substituted 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl; a substituted benzo[b]thiophenyl, for example, a substituted 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thiophenyl; or a substituted indolyl, for example, a substituted indole-2-yl, -3-yl, -4-yl, -5-yl, -6-yl, or -7-yl.

280. Cy 3B Substitution C 3～10 A compound or salt thereof according to any one of claims 222 to 264, wherein the compound is a cycloalkyl compound.

281. Cy 3B The compound or salt thereof according to claim 280, wherein is substituted cyclopentyl, cyclohexyl, or cycloheptyl.

282. Cy 3B A compound or salt thereof according to any one of claims 222 to 264, wherein is a substituted 4- to 10-membered heterocycloalkyl group.

283. Cy 3B However, R Cy3B , halogen, and C 1～6 Each R is substituted with one, two, three, four, or five substituents independently selected from the haloalkyl groups; Cy3B C 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl and C 6～10 Selected from aryl or 5- to 10-membered heteroaryl, R Cy3B Each C that forms 6～10 Aryl or 5- to 10-membered heteroaryl compounds, either unsubstituted or halogenated, C 1～6 Alkyl, C 2～6 Alkenil, C 2～6 A compound or salt thereof according to any one of claims 275 to 282, substituted with one, two, or three substituents independently selected from alkynyl and haloalkyl groups.

284. R 33 However, the following is based on: Phenyl; Benzyl; 2-phenylethyl; 2,3-dihydro-1H-inden-2-yl; 2-(2-methylphenyl)ethyl; 2-(3-methylphenyl)ethyl; 2-(4-methylphenyl)ethyl; 2-(2,4-dimethylphenyl)ethyl; 2-(2,5-dimethylphenyl)ethyl; 2-(3,5-dimethylphenyl)ethyl; 2-(2-ethylphenyl)ethyl; 2-(3-ethylphenyl)ethyl; 2-(4-ethylphenyl)ethyl; 2-(2,4-diethylphenyl)ethyl; 2-(2,5-dimethylphenyl)ethyl; 2-(3,5-dimethylphenyl)ethyl; 2-(2-trifluoromethylphenyl)ethyl; 2-(3-trifluoromethylphenyl)ethyl; 2-(4-trifluoromethylphenyl)ethyl; 2-(2-fluorophenyl)ethyl; 2-(3-fluorophenyl)ethyl; 2-(4-fluorophenyl)ethyl; 2-(2,4-difluorophenyl)ethyl; 2-(2,5-difluorophenyl)ethyl; 2-(3,5-difluorophenyl)ethyl; 2-(2-chlorophenyl)ethyl; 2-(3-chlorophenyl)ethyl; 2-(4-chlorophenyl)ethyl; 2-(2,4-dichlorophenyl)ethyl; 2-(2,5-dichlorophenyl)ethyl; 2-(3,5-dichlorophenyl)ethyl; 2-(2-methoxyphenyl)ethyl; 2-(3-methoxyphenyl)ethyl; 2-(4-methoxyphenyl)ethyl; 2-(2,4-dimethoxyphenyl)ethyl; 2-(2,5-dimethoxyphenyl)ethyl; 2-(3,5-dimethoxyphenyl)ethyl; 2-(cyclopentyl)ethyl; 2-(cyclohexyl)ethyl; 2-(cycloheptyl)ethyl; 2-(2-(aminomethyl)phenyl)ethyl; 2-(3-(aminomethyl)phenyl)ethyl; 2-(4-(aminomethyl)phenyl)ethyl; 2-(2-cyanophenyl)ethyl; 2-(3-cyanophenyl)ethyl; and 2-(4-cyanophenyl)ethyl; and The basis of the following formula: A compound or salt thereof according to any one of claims 222 to 283, selected from among them.

285. R 34 A compound or salt thereof according to any one of claims 222 to 284, wherein is hydrogen.

286. R 34 C 1～6 A compound or salt thereof according to any one of claims 222 to 284, wherein the compound is alkyl, for example, methyl.

287. R 35 A compound or salt thereof according to any one of claims 222 to 286, wherein is H.

288. R 35 Cy 3C The compound or salt thereof according to any one of claims 222 to 286.

289. R 35 is non-substituted C 1～6 A compound or salt thereof according to any one of claims 222 to 286, wherein the compound is alkyl.

290. R 35 Substitution C 1～6 A compound or salt thereof according to any one of claims 222 to 286, wherein the compound is alkyl.

291. R 35 Substitution C that forms 1～6 The alkyl group is substituted with at least one substituent, R 35 The substituents of Cy 3C , halogen, CN, OR a31 , SR a31 , C(O)R b31 , C(O)NR c31 R d31 , C(O)OR a31 ,OC(O)R b31 , OC(O)NR c31 R d31 , NR c31 R d31 , NR c31 C(O)R b31 , NR c31 C(O)NR c31 R d31 , NR c31 C(O)OR a31 , C(=NR e31 )NR c31 R d31 , NR c31 C(=NR e31 )NR c31 R d31 , S(O)R b31 , S(O)NR c31 R d31 , S(O) 2 R b31 , NR c31 S(O) 2 R b31 , S(O) 2 NR c31 R d31 The compound or a salt thereof according to claim 290, wherein one, two, or three substituents selected from the group consisting of , and oxo are selected.

292. R 35 Substitution C that forms 1～6 The alkyl group is substituted with at least one substituent, and the substituent is Cy 3C A compound or salt thereof according to claim 290 or 291, comprising:

293. R 35 Substitution C that forms 1～6 The alkyl group is substituted with one substituent, and the substituent is Cy 3C The compound or salt thereof according to claim 292.

294. R 35 (CH 2 ) 1～5 Cy 3C The compound or salt thereof according to any one of claims 290 to 293.

295. R 35 CH 2 Cy 3C The compound or salt thereof according to claim 294.

296. Cy 3C is non-substituted C 6～10 A compound or salt thereof according to any one of claims 222 to 295, wherein the compound is aryl.

297. Cy 3C The compound or salt thereof according to claim 296, wherein is an unsubstituted phenyl or naphthyl, for example, 1-naphthyl or 2-naphthyl.

298. Cy 3C A compound or salt thereof according to any one of claims 222 to 295, wherein is an unsubstituted 5- to 10-membered heteroaryl compound.

299. Cy 3C The compound or salt thereof according to claim 298, wherein is an unsubstituted pyridyl, e.g., unsubstituted 2-, 3-, or 4-pyridyl; an unsubstituted quinolyl, e.g., unsubstituted 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl; an unsubstituted benzo[b]thiophenyl, e.g., unsubstituted 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thiophenyl; or an unsubstituted indolyl, e.g., unsubstituted indole-2-yl, -3-yl, -4-yl, -5-yl, -6-yl, or -7-yl.

300. Cy 3C is non-substituted C 3～10 A compound or salt thereof according to any one of claims 222 to 295, which is a cycloalkyl compound, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.

301. Cy 3C A compound or salt thereof according to any one of claims 222 to 295, wherein is an unsubstituted 4 to 10-membered heterocycloalkyl group.

302. Cy 3C Substitution C 6～10 A compound or salt thereof according to any one of claims 222 to 295, wherein the compound is aryl.

303. Cy 3C The compound or salt thereof according to claim 302, wherein is a substituted phenyl or substituted naphthyl, for example, substituted 1-naphthyl or 2-naphthyl.

304. Cy 3C A compound or salt thereof according to any one of claims 222 to 295, wherein is a substituted 5- to 10-membered heteroaryl compound.

305. Cy 3C The compound or salt thereof according to claim 304, wherein is a substituted pyridyl, for example, a substituted 2-, 3-, or 4-pyridyl; a substituted quinolyl, for example, a substituted 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl; a substituted benzo[b]thiophenyl, for example, a substituted 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thiophenyl; or a substituted indolyl, for example, a substituted indole-2-yl, -3-yl, -4-yl, -5-yl, -6-yl, or -7-yl.

306. Cy 3C Substitution C 3～10 A compound or salt thereof according to any one of claims 222 to 295, which is a cycloalkyl, for example, substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.

307. Cy 3C A compound or salt thereof according to any one of claims 222 to 295, wherein is a substituted 4- to 10-membered heterocycloalkyl group.

308. R 36 A compound or salt thereof according to any one of claims 222 to 307, wherein is H.

309. R 36 C 1～6 A compound or salt thereof according to any one of claims 222 to 307, wherein the compound is alkyl, for example, methyl.

310. R a31 , R b31 , R c31 , R d31 , R a32 , R b32 , R c32 , and R d32 H and C are independent of each other. 1～6 A compound or salt thereof according to any one of claims 222 to 309, selected from alkyl groups.

311. Each R e31 and each R e32 A compound or salt thereof according to any one of claims 222 to 310, wherein is H.

312. A pharmaceutical composition comprising a compound according to any one of claims 222 to 311 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

313. Compounds of formula (IV) or salts thereof for use in the treatment of MASP-2 related diseases or disorders: During the ceremony, Cy 4A is either non-substituted or substituted C 6～10 It is an aryl or unsubstituted or substituted 5- to 10-membered heteroaryl; Cy 4A The ring atoms of the 5-10 membered heteroaryl that form the Cy 4A Substitution C that forms 6～10 Aryl or substituted 5-10 member heteroaryls are R Cy4A , halogen, C 1～6 Haloalkyl, CN, OR a41 , SR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)OR a41 ,OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)NR c41 R d41 , NR c41 C(O)OR a41 , C(=NR e41 )NR c41 R d41 , C(=NOR a41 )NR c41 R d41 , C(=NOC(O)R b41 )NR c41 R d41 , C(=NR e41 )NR c41 C(O)OR a41 , NR c41 C(=NR e41 )NR c41 R d41 , S(O)R b41 , S(O)NR c41 R d41 , S(O) 2 R b41 , NR c41 S(O) 2 R b41 , S(O) 2 NR c41 R d41 Substituted with one, two, three, four, or five substituents independently selected from the , and oxo; Each R Cy4A C is independent 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Selected from cycloalkyl and 4- to 10-membered heterocycloalkyl groups, R Cy4A The ring atoms of the 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl groups that form the ring consist of one, two, three, or four heteroatoms selected from carbon atoms and O, N, and S, R Cy4A Each C that forms 1～6 Alkyl, C 2～6 Alkenyl, or C 2～6 Alkynnyls are independently unsubstituted or halogen, CN, OR a41 , SR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)OR a41 ,OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)NR c41 R d41 , NR c41 C(O)OR a41 , C(=NR e41 )NR c41 R d41 , NR c41 C(=NR e41 )NR c41 R d41 , S(O)R b41 , S(O)NR c41 R d41 , S(O) 2 R b41 , NR c41 S(O) 2 R b41 , S(O) 2 NR c41 R d41 , and are substituted with one, two, or three substituents independently selected from the oxo, R Cy4A Each C that forms 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Cycloalkyls and 4- to 10-membered heterocycloalkyls are independently unsubstituted or halogenated. 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 1～6 Haloalkyl, CN, OR a41 , SR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)OR a41 ,OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)NR c41 R d41 , NR c41 C(O)OR a41 , C(=NR e41 )NR c41 R d41 , NR c41 C(=NR e41 )NR c41 R d41 , S(O)R b41 , S(O)NR c41 R d41 , S(O) 2 R b41 , NR c41 S(O) 2 R b41 , S(O) 2 NR c41 R d41 , and are substituted with one, two, or three substituents independently selected from the oxo; R 41 is H, or C 1～6 Alkyl, C 6～10 Aryl-C 1～6 Alkyl or 5-10 member heteroaryl-C 1～6 It is alkyl, R 41 C that forms 1～6 Alkyls are either unsubstituted or contain halogens, CN, OR a41 , SR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)OR a41 ,OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)NR c41 R d41 , NR c41 C(O)OR a41 , C(=NR e41 )NR c41 R d41 , NR c41 C(=NR e41 )NR c41 R d41 , S(O)R b41 , S(O)NR c41 R d41 , S(O) 2 R b41 , NR c41 S(O) 2 R b41 , S(O) 2 NR c41 R d41 , and are substituted with one, two, or three substituents independently selected from the oxo, R 41 C that forms 6～10 Aryl-C 1～6 Alkyl or 5-10 member heteroaryl-C 1～6 Alkyl is either unsubstituted or C 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 1～6 Haloalkyl, CN, OR a41 , SR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)OR a41 ,OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)NR c41 R d41 , NR c41 C(O)OR a41 , C(=NR e41 )NR c41 R d41 , NR c41 C(=NR e41 )NR c41 R d41 , S(O)R b41 , S(O)NR c41 R d41 , S(O) 2 R b41 , NR c41 S(O) 2 R b41 , S(O) 2 NR c41 R d41 , and are substituted with one, two, or three substituents independently selected from the oxo; R 42 H, C 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, or Cy 4B And; R 42 C that forms 1～6 Alkyl, C 2～6 Alkenyl, or C 2～6 Each alkynyl is either unsubstituted or Cy 4B , halogen, CN, OR a41 , SR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)OR a41 ,OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)NR c41 R d41 , NR c41 C(O)OR a41 , C(=NR e41 )NR c41 R d41 , NR c41 C(=NR e41 )NR c41 R d41 , S(O)R b41 , S(O)NR c41 R d41 , S(O) 2 R b41 , NR c41 S(O) 2 R b41 , S(O) 2 NR c41 R d41 It is substituted with one, two, three, four, or five substituents selected from the group consisting of , and oxo; however, one or fewer substituents are Cy 4B and; Cy 4B is either non-substituted or substituted C 6～10 Aryl, unsubstituted or substituted 5- to 10-membered heteroaryl, unsubstituted or substituted C 3～10 Cycloalkyl, or unsubstituted or substituted 4- to 10-membered heterocycloalkyl; Cy 4B The ring atoms of the 5-10 membered heteroaryl or unsubstituted or substituted 4-10 membered heterocycloalkyl rings consist of one, two, or three heteroatoms selected from carbon atoms and O, N, and S; Cy 4B Substitution C that forms 6～10 Aryl, substituted 5-10 member heteroaryl, substituted C 3～10 Cycloalkyls, or 4- to 10-membered heterocycloalkyls, R Cy4B , halogen, C 1～6 Haloalkyl, CN, OR a41 , SR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)OR a41 ,OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)NR c41 R d41 , NR c41 C(O)OR a41 , C(=NR e41 )NR c41 R d41 , C(=NOR a41 )NR c41 R d41 , C(=NOC(O)R b41 )NR c41 R d41 , C(=NR e41 )NR c41 C(O)OR a41 , NR c41 C(=NR e41 )NR c41 R d41 , S(O)R b41 , S(O)NR c41 R d41 , S(O) 2 R b41 , NR c41 S(O) 2 R b41 , S(O) 2 NR c41 R d41 Substituted with one, two, three, four, or five substituents independently selected from the , and oxo; Each R Cy4B C is independent 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Selected from cycloalkyl and 4- to 10-membered heterocycloalkyl groups, R Cy4B The ring atoms of the 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl groups that form the ring consist of one, two, or three heteroatoms selected from carbon atoms and O, N, and S, R Cy4B Each C that forms 1～6 Alkyl, C 2～6 Alkenyl, or C 2～6 Alkynnyls are independently unsubstituted or halogen, CN, OR a41 , SR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)OR a41 ,OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)NR c41 R d41 , NR c41 C(O)OR a41 , C(=NR e41 )NR c41 R d41 , NR c41 C(=NR e41 )NR c41 R d41 , S(O)R b41 , S(O)NR c41 R d41 , S(O) 2 R b41 , NR c41 S(O) 2 R b41 , S(O) 2 NR c41 R d41 , and are substituted with one, two, or three substituents independently selected from the oxo; each R Cy4B Each C that forms 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Cycloalkyls and 4- to 10-membered heterocycloalkyls are independently unsubstituted or halogenated. 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 1～6 Haloalkyl, CN, OR a41 , SR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)OR a41 ,OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)NR c41 R d41 , NR c41 C(O)OR a41 , C(=NR e41 )NR c41 R d41 , NR c41 C(=NR e41 )NR c41 R d41 , S(O)R b41 , S(O)NR c41 R d41 , S(O) 2 R b41 , NR c41 S(O) 2 R b41 , S(O) 2 NR c41 R d41 , and are substituted with one, two, or three substituents independently selected from the oxo; or, R 41 and R 42 These are the atoms to which they are bonded, as well as R 41 and R 42 Together with the nitrogen atom linking the bonded atom, it forms a 4-7 membered heterocycloalkyl ring, which is R Cy4B , halogen, C 1～6 Haloalkyl, CN, OR a41 , SR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)OR a41 ,OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)NR c41 R d41 , NR c41 C(O)OR a41 , C(=NR e41 )NR c41 R d41 , C(=NOR a41 )NR c41 R d41 , C(=NOC(O)R b41 )NR c41 R d41 , C(=NR e41 )NR c41 C(O)OR a41 , NR c41 C(=NR e41 )NR c41 R d41 , S(O)R b41 , S(O)NR c41 R d41 , S(O) 2 R b41 , NR c41 S(O) 2 R b41 , S(O) 2 NR c41 R d41 They may be further substituted with one, two, three, four, or five substituents independently selected from the oxo; R 43 H, C 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, or Cy 4C And; R 43 C that forms 1～6 Alkyl, C 2～6 Alkenyl, or C 2～6 Each alkynyl is either unsubstituted or Cy 4C , halogen, CN, OR a41 , SR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)OR a41 ,OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)NR c41 R d41 , NR c41 C(O)OR a41 , C(=NR e41 )NR c41 R d41 , NR c41 C(=NR e41 )NR c41 R d41 , S(O)R b41 , S(O)NR c41 R d41 , S(O) 2 R b41 , NR c41 S(O) 2 R b41 , S(O) 2 NR c41 R d41 Substituting with 1, 2, 3, 4, or 5 substituents independently selected from 0, 1, 2, 3, 4, or 5 substituents selected from the group consisting of , and oxo, provided that R 43 C that forms 1～6 Alkyl, C 2～6 Alkenyl, or C 2～6 The substituents of the alkynyl molecule are Cy 4C and; Cy 4C is either non-substituted or substituted C 6～10 Aryl, unsubstituted or substituted 5- to 10-membered heteroaryl, unsubstituted or substituted C 3～10 Cycloalkyl, or unsubstituted or substituted 4- to 10-membered heterocycloalkyl; Cy 4B The ring atoms of the 5-10 membered heteroaryl or unsubstituted or substituted 4-10 membered heterocycloalkyl rings consist of one, two, or three heteroatoms selected from carbon atoms and O, N, and S; Cy 4C Substitution C that forms 6～10 Aryl, substituted 5-10 member heteroaryl, substituted C 3～10 Cycloalkyls, or 4- to 10-membered heterocycloalkyls, R Cy4C , halogen, C 1～6 Haloalkyl, CN, OR a41 , SR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)OR a41 ,OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)NR c41 R d41 , NR c41 C(O)OR a41 , C(=NR e41 )NR c41 R d41 , C(=NOR a41 )NR c41 R d41 , C(=NOC(O)R b41 )NR c41 R d41 , C(=NR e41 )NR c41 C(O)OR a41 , NR c41 C(=NR e41 )NR c41 R d41 , S(O)R b41 , S(O)NR c41 R d41 , S(O) 2 R b41 , NR c41 S(O) 2 R b41 , S(O) 2 NR c41 R d41 Substituted with one, two, three, four, or five substituents independently selected from the , and oxo; Each R Cy4C C is independent 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Selected from cycloalkyl and 4- to 10-membered heterocycloalkyl groups, R Cy4C The ring atoms of the 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl groups that form the ring consist of one, two, or three heteroatoms selected from carbon atoms and O, N, and S, R Cy4C Each C that forms 1～6 Alkyl, C 2～6 Alkenyl, or C 2～6 Alkynnyls are independently unsubstituted or halogen, CN, OR a41 , SR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)OR a41 ,OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)NR c41 R d41 , NR c41 C(O)OR a41 , C(=NR e41 )NR c41 R d41 , NR c41 C(=NR e41 )NR c41 R d41 , S(O)R b41 , S(O)NR c41 R d41 , S(O) 2 R b41 , NR c41 S(O) 2 R b41 , S(O) 2 NR c41 R d41 , and are substituted with one, two, or three substituents independently selected from the oxo; each R Cy4A Each C that forms 6～10 Aryl, 5-10 membered heteroaryl, C 3～10 Cycloalkyls and 4- to 10-membered heterocycloalkyls are independently unsubstituted or halogenated. 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 1～6 Haloalkyl, CN, OR a41 , SR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)OR a41 ,OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)NR c41 R d41 , NR c41 C(O)OR a41 , C(=NR e41 )NR c41 R d41 , NR c41 C(=NR e41 )NR c41 R d41 , S(O)R b41 , S(O)NR c41 R d41 , S(O) 2 R b41 , NR c41 S(O) 2 R b41 , S(O) 2 NR c41 R d41 , and are substituted with one, two, or three substituents independently selected from the oxo; R a41 , R b41 , R c41 , and R d41 H and C are independent of each other. 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 6～10 Ariel, C 3～7 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6～10 Aryl-C 1～3 Alkyl, 5-10 member heteroaryl-C 1～3 Alkyl, C 3～7 Cycloalkyl-C 1～3 Alkyl and 4- to 10-membered heterocycloalkyl-C 1～3 Selected from alkyl groups, R a41 , R b41 , R c41 , and R d41 The C that forms 1～6 Alkyl, C 2～6 Alkenil, C 2～6 Alkinyl, C 6～10 Ariel, C 3～7 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6～10 Aryl-C 1～3 Alkyl, 5-10 member heteroaryl-C 1～3 Alkyl, C 3～7 Cycloalkyl-C 1～3 Alkyl and 4- to 10-membered heterocycloalkyl-C 1～3 Each alkyl group is C 1～6 Alkyl, Halo, CN, OR a42 , SR a42 , C(O)R b42 , C(O)NR c42 R d42 , C(O)OR a42 ,OC(O)R b42 , OC(O)NR c42 R d42 , NR c42 R d42 , NR c42 C(O)R b42 , NR c42 C(O)NR c42 R d42 , NR c42 C(O)OR a42 , C(=NR e42 )NR c42 R d42 , NR c42 C(=NR e42 )NR c42 R d42 , S(O)R b42 , S(O)NR c42 R d42 , S(O) 2 R b42 , NR c42 S(O) 2 R b42 , S(O) 2 NR c42 R d42 , and may be substituted with one, two, three, four, or five substituents independently selected from the oxo; or, R bonded to the same N atom c41 and R d41 These, together with the N atom to which they are both bonded, form a 4-membered, 5-membered, 6-membered, or 7-membered heterocycloalkyl group or a 5-membered heteroaryl group, each being C 1～6 Alkyl, Halo, CN, OR a42 , SR a42 , C(O)R b42 , C(O)NR c42 R d42 , C(O)OR a42 ,OC(O)R b42 , OC(O)NR c42 R d42 , NR c42 R d42 , NR c42 C(O)R b42 , NR c42 C(O)NR c42 R d42 , NR c42 C(O)OR a42 , C(=NR e42 )NR c42 R d42 , NR c42 C(=NR e42 )NR c42 R d42 , S(O)R b42 , S(O)NR c42 R d42 , S(O) 2 R b42 , NR c42 S(O) 2 R b42 , S(O) 2 NR c42 R d42 , and may be substituted with one, two, or three substituents independently selected from the oxo; R a42 , R b42 , R c42 , and R d42 H and C are independent of each other. 1～6 Alkyl, C 1～6 Haloalkyl, C 2～6 Alkenil, C 2～6 Alkinyl, phenyl, C 3～7 Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C 1～3 Alkyl, 5-6 member heteroaryl-C 1～3 Alkyl, C 3～7 Cycloalkyl-C 1～3 Alkyl and 4- to 7-membered heterocycloalkyl-C 1～3 Selected from alkyl groups, R a42 , R b42 , R c42 , and R d42 The C that forms 1～6 Alkyl, C 1～6 Haloalkyl, C 2～6 Alkenil, C 2～6 Alkinyl, phenyl, C 3～7 Cycloalkyl, 5-6 member heteroaryl, 4-7 member heterocycloalkyl, phenyl-C 1～3 Alkyl, 5-6 member heteroaryl-C 1～3 Alkyl, C 3～7 Cycloalkyl-C 1～3 Alkyl and 4- to 7-membered heterocycloalkyl-C 1～3 Alkyl compounds are OH, CN, amino, and NH(C) respectively. 1～6 Alkyl), N(C 1～6 Alkyl) 2 Hello, C 1～6 Alkyl, C 1～6 Alkoxy, C 1～6 Haloalkyl, C 1～6 It may be substituted with one, two, or three substituents independently selected from haloalkoxys and oxos; or, R bonded to the same N atom c42 and R d42 These, together with the N atom to which they are both bonded, form a 4-membered, 5-membered, 6-membered, or 7-membered heterocycloalkyl group or a 5-membered heteroaryl group, each of which is either unsubstituted or OH, CN, amino, or NH(C) 1～6 Alkyl), N(C 1～6 Alkyl) 2 Hello, C 1～6 Alkyl, C 1～6 Alkoxy, C 1～6 Haloalkyl, C 1～6 Substituted with one, two, or three substituents independently selected from haloalkoxys and oxos; R e41 and R e42 These are H, CN, or NO, respectively, independently. 2 That is the case.

314. Cy 4A The compound or salt thereof according to claim 313, wherein is unsubstituted or substituted aryl.

315. Cy 4A The compound or salt thereof according to claim 314, wherein is an unsubstituted or substituted phenyl.

316. Cy 4A The compound or a salt thereof according to claim 315, wherein is a substituted phenyl.

317. Cy 4A at least one OR a41 or at least one C(=NR) e41 )NR c41 R d41 , C(=NOR a41 )NR c41 R d41 , C(=NOC(O)R b41 )NR c41 R d41 , or C(=NR e41 )NR c41 C(O)OR a41 A compound or salt thereof according to any one of claims 313 to 316, which is substituted with [the compound or salt thereof].

318. Cy 4A at least one OR a41 It is replaced with and C 1～6 Alkyl, C 1～6 A compound or salt thereof according to any one of claims 313 to 317, substituted with at least one further substituent selected from the group consisting of haloalkyls and halogens.

319. Cy 4A It is substituted with at least one OH group, and C 1～6 Alkyl, C 1～6 A compound or salt thereof according to any one of claims 313 to 318, substituted with at least one further substituent selected from the group consisting of haloalkyls and halogens.

320. Cy 4A Preferably at position 4, at least one C(=NR e41 )NR c41 R d41 , C(=NOR a41 )NR c41 R d41 , C(=NOC(O)R b41 )NR c41 R d41 , C(=NR e41 )NR c41 C(O)OR a41 A compound or salt thereof according to any one of claims 313 to 319, which is substituted with

321. Cy 4A Preferably at position 4, at least one C(=NR e41 )NR c41 R d41 For example, C(=NH)NH 2 A compound or salt thereof according to claim 320, which is substituted with

322. Cy 4A The formula is as follows: The compound or salt thereof according to claim 316, which is any one of the following.

323. Cy 4A In the formula defining R a41 C 1～6 Alkyl, for example, methyl, R b41 C 1～6 Alkyl, for example, methyl, R b41 C 1～6 Haloalkyls, for example, trifluoromethyl, R c41 The compound or a salt thereof according to claim 322, wherein is alkyl, for example, methyl.

324. Cy 4A The compound or salt thereof according to claim 313, wherein is unsubstituted or substituted heteroaryl.

325. Cy 4A The compound or salt thereof according to claim 324, wherein is unsubstituted or substituted pyridine-3-yl, 1H-pyrrolo[2,3-b]pyridine-5-yl, or 1H-benzo[d]imidazole-6-yl.

326. Cy 4A The formula is as follows: A compound or salt thereof according to claim 324 or 325, which is any one of the above.

327. Cy 4A Each R in the formula defining Cy4AA C 1～6 The compound or a salt thereof according to claim 326, wherein the compound is an alkyl group, for example methyl or ethyl, preferably methyl, or a halogen, for example F, Cl, or Br, preferably Cl.

328. Cy 4A Each R bonded to nitrogen in the formula defining the Cy4A C 1～6 The compound or a salt thereof according to claim 326 or 327, wherein the compound is alkyl, for example, methyl or ethyl.

329. R 41 A compound or salt thereof according to any one of claims 313 to 328, wherein is H.

330. R 41 C 1～6 A compound or salt thereof according to any one of claims 313 to 328, wherein the compound is alkyl.

331. R 41 The compound or a salt thereof according to claim 330, wherein the compound is methyl.

332. R 42 A compound or salt thereof according to any one of claims 313 to 331, wherein is H.

333. R 42 is non-substituted C 1～6 A compound or salt thereof according to any one of claims 313 to 331, wherein the compound is alkyl, for example, methyl.

334. R 42 Cy 4B The compound or salt thereof according to any one of claims 313 to 331.

335. R 42 Substitution C 1～6 Alkyl, C 2～6 Alkenyl, or C 2～6 A compound or salt thereof according to any one of claims 313 to 331, which is an alkynyl.

336. R 42 Substitution C 1～6 The compound or a salt thereof according to claim 335, wherein it is alkyl.

337. R 42 Substitution C 1～6 It is alkyl, R 42 C that forms 1～6 Alkyl, Cy 4B , halogen, CN, OR a41 , SR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)OR a41 ,OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)NR c41 R d41 , NR c41 C(O)OR a41 , C(=NR e41 )NR c41 R d41 , NR c41 C(=NR e41 )NR c41 R d41 , S(O)R b41 , S(O)NR c41 R d41 , S(O) 2 R b41 , NR c41 S(O) 2 R b41 , S(O) 2 NR c41 R d41 Substituting with one, two, or three substituents selected from the group consisting of , and oxo; provided that one or fewer substituents are Cy 4B The compound or salt thereof according to claim 335.

338. R 42 Substitution C that forms 1～6 The alkyl group is substituted with at least one substituent, and the substituent is Cy 4B A compound or salt thereof according to claim 336 or 337, comprising:

339. R 35 Substitution C that forms 1～6 The alkyl group is substituted with one substituent, and the substituent is Cy 4B The compound or salt thereof according to claim 338.

340. R 42 (CH 2 ) 1～5 Cy 4B The compound or salt thereof according to claim 339.

341. R 42 CH 2 Cy 4B The compound or salt thereof according to claim 340.

342. Cy 4B is non-substituted C 6～10 Aryl, for example, unsubstituted phenyl or naphthyl, for example, 1-naphthyl or 2-naphthyl, Cy 4B is an unsubstituted 5- to 10-membered heteroaryl, for example, unsubstituted pyridyl, for example, unsubstituted 2-, 3-, or 4-pyridyl; unsubstituted quinolyl, for example, unsubstituted 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl; unsubstituted benzo[b]thiophenyl, for example, unsubstituted 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thiophenyl; or unsubstituted indolyl, for example, unsubstituted indole-2-yl, -3-yl, -4-yl, -5-yl, -6-yl, or -7-yl, and Cy 4B is non-substituted C 3～10 Cycloalkyl, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, or Cy 4B A compound or salt thereof according to any one of claims 313 to 341, wherein is an unsubstituted 4 to 10-membered heterocycloalkyl group.

343. Cy 4B Substitution C 6～10 Aryl, for example substituted phenyl or naphthyl, for example 1-naphthyl or 2-naphthyl, Cy 4B is a substituted 5- to 10-membered heteroaryl, for example, a substituted pyridyl, for example, a substituted 2-, 3-, or 4-pyridyl; a substituted quinolyl, for example, a substituted 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl; a substituted benzo[b]thiophenyl, for example, a substituted 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thiophenyl; or a substituted indolyl, for example, a substituted indole-2-yl, -3-yl, -4-yl, -5-yl, -6-yl, or -7-yl, and Cy 4B Substitution C 3～10 Cycloalkyl, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, or Cy 4B A compound or salt thereof according to any one of claims 313 to 341, wherein is a substituted 4- to 10-membered heterocycloalkyl group.

344. R 41 and R 42 However, the atoms to which they are bonded, as well as R 41 and R 42 Together with the nitrogen atom linking the bonded atom, it forms a 4-7 membered heterocycloalkyl ring, which is R Cy4B , halogen, C 1～6 Haloalkyl, CN, OR a41 , SR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)OR a41 ,OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)NR c41 R d41 , NR c41 C(O)OR a41 , C(=NR e41 )NR c41 R d41 , C(=NOR a41 )NR c41 R d41 , C(=NOC(O)R b41 )NR c41 R d41 , C(=NR e41 )NR c41 C(O)OR a41 , NR c41 C(=NR e41 )NR c41 R d41 , S(O)R b41 , S(O)NR c41 R d41 , S(O) 2 R b41 , NR c41 S(O) 2 R b41 , S(O) 2 NR c41 R d41 The compound or salt thereof according to any one of claims 313 to 328, which may be further substituted with one, two, three, four, or five substituents independently selected from the oxo and the compound.

345. R 41 and R 42 However, the atoms to which they are bonded, as well as R 41 and R 42 The compound or salt thereof according to claim 344, wherein the bonded atom, together with a nitrogen atom linking the bonded atom, forms a five-membered or six-membered heterocycloalkyl ring.

346. The following equations (IV-1), (IV-2), (IV-1a), (IV-1b), (IV-2a), or (IV-2b): A compound or salt thereof according to claim 345, which matches any of the following.

347. R 43 Cy 4C The compound or salt thereof according to any one of claims 313 to 346.

348. R 43 is non-substituted C 1～6 A compound or salt thereof according to any one of claims 313 to 346, wherein the compound is alkyl.

349. R 43 Substitution C 1～6 A compound or salt thereof according to any one of claims 313 to 346, wherein the compound is alkyl.

350. R 43 Substitution C that forms 1～6 Alkyl, Cy 4C , halogen, CN, OR a41 , SR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)OR a41 ,OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)NR c41 R d41 , NR c41 C(O)OR a41 , C(=NR e41 )NR c41 R d41 , NR c41 C(=NR e41 )NR c41 R d41 , S(O)R b41 , S(O)NR c41 R d41 , S(O) 2 R b41 , NR c41 S(O) 2 R b41 , S(O) 2 NR c41 R d41 The compound or salt thereof according to claim 349, substituted with at least one substituent independently selected from one, two, or three substituents selected from the group consisting of , and oxo.

351. R 43 Substitution C that forms 1～6 The alkyl group is substituted with at least one substituent, and the substituent is Cy 4C A compound or salt thereof according to claim 349 or 350, comprising:

352. R 43 Substitution C that forms 1～6 The alkyl group is substituted with one substituent, and the substituent is Cy 4C The compound or salt thereof according to claim 351.

353. R 43 (CH 2 ) 1～5 Cy 4C The compound or salt thereof according to any one of claims 349 to 352.

354. R 43 CH 2 Cy 4C The compound or salt thereof according to claim 353.

355. R 43 CH 2 CH 2 Cy 4C The compound or salt thereof according to claim 353.

356. R 43 ga CF 2 Cy 4C or CF 2 CH 2 Cy 4C The compound or salt thereof according to claim 351.

357. Cy 4C is non-substituted C 6～10 A compound or salt thereof according to any one of claims 313 to 356, wherein the compound is an aryl, for example, phenyl, 1-naphthyl, or 2-naphthyl.

358. Cy 4C The compound or salt thereof according to any one of claims 313 to 356, wherein is an unsubstituted 5- to 10-membered heteroaryl, for example, unsubstituted pyridyl, for example, unsubstituted 2-, 3-, or 4-pyridyl; an unsubstituted quinolyl, for example, unsubstituted 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl; an unsubstituted benzo[b]thiophenyl, for example, unsubstituted 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thiophenyl; or an unsubstituted indolyl, for example, unsubstituted indole-2-yl, -3-yl, -4-yl, -5-yl, -6-yl, or -7-yl.

359. Cy 4C is non-substituted C 3～10 A compound or salt thereof according to any one of claims 313 to 356, which is a cycloalkyl compound, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.

360. Cy 4C A compound or salt thereof according to any one of claims 313 to 356, wherein is an unsubstituted 4 to 10-membered heterocycloalkyl group.

361. Cy 4C Substitution C 6～10 A compound or salt thereof according to any one of claims 313 to 356, which is an aryl, for example, a substituted phenyl, a substituted 1-naphthyl, or a substituted 2-naphthyl.

362. Cy 4C The compound or salt thereof according to any one of claims 313 to 356, wherein is a substituted 5- to 10-membered heteroaryl, for example, a substituted pyridyl, for example, a substituted 2-, 3-, or 4-pyridyl; a substituted quinolyl, for example, a substituted 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl; a substituted benzo[b]thiophenyl, for example, a substituted 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thiophenyl; or a substituted indolyl, for example, a substituted indole-2-yl, -3-yl, -4-yl, -5-yl, -6-yl, or -7-yl.

363. Cy 4C Substitution C 3～10 A compound or salt thereof according to any one of claims 313 to 356, which is a cycloalkyl, for example, substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.

364. Cy 4C A compound or salt thereof according to any one of claims 313 to 356, wherein is a substituted 4- to 10-membered heterocycloalkyl group.

365. The following equations (IV-3) to (IV-7), (IV-3a), (IV-3b), (IV-5a), (IV-5b), (IV-7a), or (IV-7b): A compound or salt thereof according to any one of claims 313 to 364, which matches any one of the above.

366. R a41 , R b41 , R c41 , R d41 , R a42 , R b42 , R c42 , and R d42 H and C are independent of each other. 1～6 A compound or salt thereof according to any one of claims 313 to 365, selected from alkyl groups.

367. Each R e41 and each R e42 A compound or salt thereof according to any one of claims 313 to 366, wherein is H.

368. A pharmaceutical composition comprising a compound according to any one of claims 313 to 367 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

369. MASP-2 inhibitory compounds of formula (VA) or (VB) or a salt thereof, for therapeutic use in the treatment of MASP-2-related diseases or disorders: During the ceremony, A 1 -(C=NH)-, -(C=NOR a )-,-[C=NO(C=O)R a ]-,-[C=N[O(C=O)ZR b The member is selected from the group consisting of ]}-, condensed 5-membered or 6-membered heterocyclyls, and condensed 5-membered or 6-membered heteroaryls; A 1 If Y is -(C=NH)-, 1 wa-NH 2 -NH(C=O)R a , and -NH(C=O)ZR b Selected from the group consisting of; A 1 -(C=NOR a )-,-[C=NO(C=O)R a ]-, or -{C=N[O(C=O)ZR b ]}- If Y 1 wa-NH 2 and; A 1 If Y is a condensed heterocyclyl or heteroaryl, 1 wa-NH 2 Or it is a halo, A 1 m further R 1 It is substituted with the base; Each R a and R b C 1 ~C 6 Alkyl, C 3 ~C 10 Cycloalkyl, C 6 ~C 10 Aryl, and C 7 ~C 12 Selected from the group consisting of arylalkyl groups; R a C 1 ~C 6 Alkyl, hydroxyl, hydroxyl (C 1 ~C 6 Alkyl), C 1 ~C 6 Alkoxy, C 2 ~C 9 Alkoxyalkyl, amino, C 1 ~C 6 It has m substituents selected from the group consisting of alkylaminos and halos; or alternatively, R a and R b They came together, C 1 ~C 6 Alkyl, hydroxyl, C 1 ~C 6 A heterocyclyl ring having m substituents selected from the group consisting of alkoxys and halos is formed; Each Z is independently selected from the group consisting of O and S; A 2 C 3 ~C 6 Heteroaryl, C 6 Aryl, and C 2 ~C 6 A member selected from the group consisting of alkyl groups; A 2 C 3 ~C 6 If it is a heteroaryl, Y 2 wa-NH 2 ,-CH 2 NH 2 , chloro, -(C=NH)NH 2 -(C=NH)NH(C=O)R a -(C=NH)NH(C=O)ZR b ,-(C=NOR a )NH 2 -[C=NO(C=O)R a ]NH 2 , and -{C=N[O(C=O)ZR b ]}NH 2 Selected from the group consisting of; A 2 m further R 1 It is substituted with the base; A 2 C 6 If it is an aryl, Y 2 A is selected from the group consisting of aminomethyl, hydroxy, and halo. 2 m further R 1 It is substituted with the base; A 2 C 2 ~C 6 If it is alkyl, Y 2 is -NH(C=NH)NH 2 -NH(C=NH)NH(C=O)R a , and -NH(C=NH)NH(C=O)ZR b Selected from the group consisting of; Each R 1 C 1 ~C 6 Alkyl, hydroxyl, C 1 ~C 6 Alkoxy, amino, C 1 ~C 6 A member independently selected from the group consisting of alkylamino and halo; Each m and n is an independently selected integer between 0 and 3; L is -(O) p -(C(R 2a )(R 2b )) q -and, Each R 2a or R 2b is a member independently selected from the group consisting of hydrogen and fluoro; p is an integer between 0 and 1; q is an integer between 1 and 2; R 3 is hydrogen, C 1 ~C 6 Alkyl, C 1 ~C 6 Fluoroalkyl and carboxy(C) 1 ~C 6 A member selected from the group consisting of alkyls; or alternatively, R 3 and R 4 They combine to form an azetidine ring, a pyrrolidine ring, or a piperidine ring; R 4 is hydrogen and C 1 ~C 6 A member selected from the group consisting of alkyls; or alternatively, R 4 and R 3 They combine to form an azetidine ring, a pyrrolidine ring, or a piperidine ring; R 5 C 3 ~C 7 Cycloalkyl, C 4 ~C 8 Cycloalkylalkyl, heteroaryl, and C 7 ~C 12 Arylalkyl or heteroarylalkyl (0-3 R 13 A member selected from the group consisting of (having substituents); or alternatively, R 5 and R 6 Together, they form 0 to 3 R 13 Forming a heterocycle with substituents; R 6 is hydrogen, C 1 ~C 6 Alkyl, C 3 ~C 7 Cycloalkyl, carboxy(C 1 ~C 6 Alkyl), C 7 ~C 12 Arylalkyl or heteroarylalkyl (0-3 R 13 (Having substituents), amino(C 1 ~C 8 Alkyl, and amide (C 1 ~C 8 A member selected from the group consisting of alkyls; or alternatively, R 6 and R 5 Together, they form 0 to 3 R 13 Forming a heterocycle with substituents; Each R 13 C 1 ~C 6 Alkyl, C 6 ~C 10 Ariel, (C 6 ~C 10 Ariel)C 1 ~C 6 Alkyl, Carboxy(C) 1 ~C 6 Alkyloxy), heteroaryl, (C 6 ~C 10 (heteroaryl) C 1 ~C 6 Alkyl, heterocyclyl, hydroxyl, hydroxyl (C 1 ~C 6 Alkyl), C 1 ~C 6 Alkoxy, C 2 ~C 9 Alkoxyalkyl, amino, C 1 ~C 6 Amide, C 1 ~C 6 A member independently selected from the group consisting of alkylamino and halo; or alternatively, two R 13 The two elements combine to form a condensed C 6 ~C 10 Aryl ring, C 6 ~C 10 Heteroaryl ring, or C 5 ~C 7 It forms a cycloalkyl ring.

370. MASP-2 inhibitory compounds of formula (VA) or (VB) or a salt thereof, for therapeutic use in the treatment of MASP-2-related diseases or disorders: During the ceremony, A 1 -(C=NH)-, -(C=NOR a )-,-[C=NO(C=O)R a ]-,-[C=N[O(C=O)ZR b The member is selected from the group consisting of ]}-, condensed 5-membered or 6-membered heterocyclyls, and condensed 5-membered or 6-membered heteroaryls; A 1 If Y is -(C=NH)-, 1 wa-NH 2 -NH(C=O)R a , and -NH(C=O)ZR b Selected from the group consisting of; A 1 -(C=NOR a )-,-[C=NO(C=O)R a ]-, or -{C=N[O(C=O)ZR b ]}- If Y 1 wa-NH 2 and; A 1 If Y is a condensed heterocyclyl or heteroaryl, 1 wa-NH 2 Or it is a halo, A 1 m further R 1 It is substituted with the base; Each R a and R b C 1 ~C 6 Alkyl, C 3 ~C 10 Cycloalkyl, C 6 ~C 10 Aryl, and C 7 ~C 12 Selected from the group consisting of arylalkyl groups; R a C 1 ~C 6 Alkyl, hydroxyl, hydroxyl (C 1 ~C 6 Alkyl), C 1 ~C 6 Alkoxy, C 2 ~C 9 Alkoxyalkyl, amino, C 1 ~C 6 It has m substituents selected from the group consisting of alkylaminos and halos; or alternatively, R a and R b They came together, C 1 ~C 6 Alkyl, hydroxyl, C 1 ~C 6 A heterocyclyl ring having m substituents selected from the group consisting of alkoxys and halos is formed; Each Z is independently selected from the group consisting of O and S; A 2 C 3 ~C 6 Heteroaryl, C 6 Aryl, and C 2 ~C 6 A member selected from the group consisting of alkyl groups; A 2 C 3 ~C 6 If it is a heteroaryl, Y 2 wa-NH 2 ,-CH 2 NH 2 , chloro, -(C=NH)NH 2 -(C=NH)NH(C=O)R a -(C=NH)NH(C=O)ZR b ,-(C=NOR a )NH 2 -[C=NO(C=O)R a ]NH 2 , and -{C=N[O(C=O)ZR b ]}NH 2 Selected from the group consisting of; A 2 m further R 1 It is substituted with the base; A 2 C 6 If it is an aryl, Y 2 A is selected from the group consisting of aminomethyl, hydroxy, and halo. 2 m further R 1 It is substituted with the base; A 2 C 2 ~C 6 If it is alkyl, Y 2 is -NH(C=NH)NH 2 -NH(C=NH)NH(C=O)R a , and -NH(C=NH)NH(C=O)ZR b Selected from the group consisting of; Each R 1 C 1 ~C 6 Alkyl, hydroxyl, C 1 ~C 6 Alkoxy, amino, C 1 ~C 6 A member independently selected from the group consisting of alkylamino and halo; Each m and n is an independently selected integer between 0 and 3; L is -(O) p -(C(R 2a )(R 2b )) q -and, Each R 2a or R 2b is a member independently selected from the group consisting of hydrogen and fluoro; p is an integer between 0 and 1; q is an integer between 1 and 2; R 3 is hydrogen, C 1 ~C 6 Alkyl, C 1 ~C 6 Fluoroalkyl and carboxy(C) 1 ~C 6 A member selected from the group consisting of alkyls; or alternatively, R 3 and R 4 They combine to form an azetidine ring, a pyrrolidine ring, or a piperidine ring; R 4 is hydrogen and C 1 ~C 6 A member selected from the group consisting of alkyls; or alternatively, R 4 and R 3 They combine to form an azetidine ring, a pyrrolidine ring, or a piperidine ring; R 5 C 3 ~C 7 Cycloalkyl, C 4 ~C 8 Cycloalkylalkyl, heteroaryl, and C 7 ~C 12 Arylalkyl or heteroarylalkyl (0-3 R 13 A member selected from the group consisting of (having substituents); or alternatively, R 5 and R 6 Together, they form 0 to 3 R 13 Forming a heterocycle with substituents; R 6 is hydrogen, C 1 ~C 6 Alkyl, C 3 ~C 7 Cycloalkyl, carboxy(C 1 ~C 6 Alkyl), C 7 ~C 12 Arylalkyl or heteroarylalkyl (0-3 R 13 (Having substituents), amino(C 1 ~C 8 Alkyl, and amide (C 1 ~C 8 A member selected from the group consisting of alkyls; or alternatively, R 6 and R 5 Together, they form 0 to 3 R 13 Forming a heterocycle with substituents; Each R 13 C 1 ~C 6 Alkyl, C 6 ~C 10 Aryl, Carboxy(C) 1 ~C 6 Alkyloxy), heteroaryl, heterocyclyl, hydroxyl, hydroxyl (C 1 ~C 6 Alkyl), C 1 ~C 6 Alkoxy, C 2 ~C 9 Alkoxyalkyl, amino, C 1 ~C 6 Amide, C 1 ~C 6 A member independently selected from the group consisting of alkylamino and halo; or alternatively, two R 13 The two elements combine to form a condensed C 6 ~C 10 Aryl ring, C 6 ~C 10 Heteroaryl ring, or C 5 ~C 7 It forms a cycloalkyl ring; However, the compound is not melagatran.

371. A compound of formula VA, the compound according to claim 369 or 370, or a salt thereof.

372. A compound or salt thereof according to any one of claims 369 to 371, selected from the group consisting of compounds of formula (VC) to (VF) and salts thereof: During the ceremony, R 7 These are hydrogen, hydroxyl, and C 1 ~C 6 A member selected from the group consisting of alkyl groups; R 8 is hydrogen and C 1 ~C 6 A member selected from the group consisting of alkyl groups; Each m and n is an independently selected integer between 0 and 2.

373. R 7 A compound or salt thereof according to any one of claims 369 to 372, wherein is hydrogen.

374. R 8 A compound or salt thereof according to any one of claims 369 to 373, wherein the compound is hydrogen.

375. A 1 The compound or salt thereof according to claim 371, wherein the compound is -(C=NH)-.

376. A 1 The compound or a salt thereof according to claim 371, wherein is a condensed heteroaryl compound.

377. Y 1 ga-NH 2 The compound or salt thereof according to claim 375 or 376.

378. A compound of formula VB, according to claim 369 or 370, or a salt thereof.

379. A 2 C 6 The compound or a salt thereof according to claim 378, wherein the compound is an aryl compound.

380. Y 2 The compound or salt thereof according to claim 378 or 379, wherein is 3-chloro.

381. A 2 C 2 ~C 6 The compound or salt thereof according to claim 378, wherein it is alkyl.

382. Y 2 -NH(C=NH)NH 2 The compound or salt thereof according to any one of claims 378 to 381.

383. The following R 3 Stereochemical configuration A compound or salt thereof according to any one of claims 369 to 382, ​​which exhibits the characteristics of the compound or salt thereof.

384. R 3 The compound or salt thereof according to any one of claims 369 to 383, wherein the compound is a member selected from the group consisting of hydrogen or methyl.

385. R 3 The compound or a salt thereof according to claim 384, wherein the compound is methyl.

386. R 4 The compound or salt thereof according to any one of claims 369 to 385, wherein the compound is a member selected from the group consisting of hydrogen or methyl.

387. R 4 The compound or salt thereof according to claim 386, wherein the compound is hydrogen.

388. R 3 and R 4 A compound or salt thereof according to any one of claims 369 to 383, wherein the compounds together form an azetidine ring, a pyrrolidine ring, or a piperidine ring.

389. R 3 and R 4 The compound or salt thereof according to claim 388, wherein the compounds together form a pyrrolidine ring.

390. R 3 and R 4 The compound or salt thereof according to claim 388, wherein the two elements combine to form a piperidine ring.

391. R 5 However, 2,3-dihydro-1H-inden-2-yl, cyclohexyl, cyclohexylmethyl, phenyl, benzyl, phenethyl, and phenpropyl (0-5 R 13 A compound or salt thereof according to any one of claims 369 to 390, which is a member selected from the group consisting of (having substituents).

392. R 5 The compound or salt thereof according to claim 391, wherein the compound is a member selected from the group consisting of phenethyl, 4-methylphenethyl, 4-chlorophenethyl, 4-fluorophenethyl, 3-methylphenethyl, 3-chlorophenethyl, 3-fluorophenethyl, 2-methylphenethyl, 2-chlorophenpropyl, 2-fluorophenpropyl, phenpropyl, 4-methylphenpropyl, 4-chlorophenpropyl, 4-fluorophenpropyl, 3-methylphenpropyl, 3-chlorophenpropyl, 3-fluorophenpropyl, 2-methylphenpropyl, 2-chlorophenpropyl, and 2-fluorophenpropyl.

393. R 6 However, amino(C 1 ~C 8 Alkyl) and C 7 ~C 12 Arylalkyl (0-3 R 13 A compound or salt thereof according to any one of claims 369 to 392, which is a member selected from the group consisting of (having substituents).

394. R 6 The compound or salt thereof according to any one of claims 369 to 393, wherein the compound is a member selected from the group consisting of hydrogen and carboxymethyl.

395. R 6 and R 5 A compound or salt thereof according to any one of claims 369 to 391, wherein the compounds together form a pyrrolidine ring, an octahydro-1H-indole ring, a 3-phenylpyrrolidine ring, a piperidine ring, a 1,2,3,4-tetrahydroisoquinoline ring, a 2,5-dihydro-1H-pyrrole ring, or a 1,2,3,6-tetrahydropyridine ring.

396. R 1 is hydroxyl or C 1 ~C 6 A compound or salt thereof according to any one of claims 369 to 395, which is an alkoxy.

397. A compound or salt thereof according to any one of claims 369 to 396, wherein n is 0.

398. A compound or salt thereof according to any one of claims 369 to 397, wherein p is 0.

399. A compound or salt thereof according to any one of claims 369 to 398, wherein q is 1.

400. Each R 2a or R 2b A compound or salt thereof according to any one of claims 369 to 399, wherein the compound is hydrogen.

401. The compound or a salt thereof according to claim 400, wherein L is methylene.

402. A pharmaceutical composition comprising a compound according to any one of claims 369 to 401 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

403. MASP-2 inhibitory compounds of formula (VIA) or (VIB) or a salt thereof, for therapeutic use in the treatment of MASP-2-related diseases or disorders: During the ceremony, A 1 -(C=NH)-, -(C=NOR a )-,-[C=NO(C=O)R a ]-,-[C=N[O(C=O)ZR b The member is selected from the group consisting of ]}-, condensed 5-membered or 6-membered heterocyclyls, and condensed 5-membered or 6-membered heteroaryls; A 1 If Y is -(C=NH)-, 1 wa-NH 2 -NH(C=O)R a , and -NH(C=O)ZR b Selected from the group consisting of; A 1 -(C=NOR a )-,-[C=NO(C=O)R a ]-, or -{C=N[O(C=O)ZR b ]}- If Y 1 wa-NH 2 and; A 1 If Y is a condensed heterocyclyl or heteroaryl, 1 wa-NH 2 Or it is a halo, A 1 m further R 1 It is substituted with the base; Each R a and R b C 1 ~C 6 Alkyl, C 3 ~C 10 Cycloalkyl, C 6 ~C 10 Aryl, and C 7 ~C 12 Selected from the group consisting of arylalkyl groups; R a C 1 ~C 6 Alkyl, hydroxyl, hydroxyl (C 1 ~C 6 Alkyl), C 1 ~C 6 Alkoxy, C 2 ~C 9 Alkoxyalkyl, amino, C 1 ~C 6 It has m substituents selected from the group consisting of alkylaminos and halos; or alternatively, R a and R b They came together, C 1 ~C 6 Alkyl, hydroxyl, C 1 ~C 6 A heterocyclyl ring having m substituents selected from the group consisting of alkoxys and halos is formed; Each Z is independently selected from the group consisting of O and S; A 2 C 3 ~C 6 Heteroaryl and C 2 ~C 6 A member selected from the group consisting of alkyl groups; A 2 C 3 ~C 6 If it is a heteroaryl, Y 2 wa-NH 2 ,-CH 2 NH 2 , chloro, -(C=NH)NH 2 -(C=NH)NH(C=O)R a -(C=NH)NH(C=O)ZR b ,-(C=NOR a )NH 2 -[C=NO(C=O)R a ]NH 2 , and -{C=N[O(C=O)ZR b ]}NH 2 Selected from the group consisting of; A 2 m further R 1 It is substituted with the base; A 2 C 2 ~C 6 If it is alkyl, Y 2 is -NH(C=NH)NH 2 -NH(C=NH)NH(C=O)R a , and -NH(C=NH)NH(C=O)ZR b Selected from the group consisting of; Each R 1 C 1 ~C 6 Alkyl, hydroxyl, C 1 ~C 6 Alkoxy, amino, C 1 ~C 6 A member independently selected from the group consisting of alkylamino and halo; Each m and n is an independently selected integer between 0 and 3; X and X 2 These are, respectively, NR 8 , CH, and CR 10 A member selected from the group consisting of; Each R 8 is hydrogen and C 1 ~C 6 A member independently selected from the group consisting of alkyl groups; Each R 10 C 1 ~C 6 Alkyl, heteroaryl, or C 6 ~C 10 Aryl (0 to 3 R 13 (having substituents), hydroxyl, hydroxyl (C 1 ~C 6 Alkyl), C 1 ~C 6 Alkoxy, C 2 ~C 9 Alkoxyalkyl, amino, C 1 ~C 6 A member independently selected from the group consisting of alkylamino and halo; or alternatively, two R 10 The two elements come together in a condensation C 6 Aryl ring, heteroaryl ring, or C 5 ~C 7 Cycloalkyl ring (0 to 3 R 13 Forms (having substituents); r is an integer between 0 and 4; Each R 13 C 1 ~C 6 Alkyl, C 6 ~C 10 Aryl, Carboxy(C) 1 ~C 6 Alkyloxy), heteroaryl, heterocyclyl, hydroxyl, hydroxyl (C 1 ~C 6 Alkyl), C 1 ~C 6 Alkoxy, C 2 ~C 9 Alkoxyalkyl, amino, C 1 ~C 6 Amide, C 1 ~C 6 A member independently selected from the group consisting of alkylamino and halo; or alternatively, two R 13 The two elements combine to form a condensed C 6 ~C 10 Aryl ring, C 6 ~C 10 Heteroaryl ring, or C 5 ~C 7 It forms a cycloalkyl ring.

404. A compound according to claim 403 or a salt thereof, selected from the group consisting of compounds of the following formula and salts thereof: During the ceremony, Each R 7 These are hydrogen, hydroxyl, and C 1 ~C 6 A member selected from the group consisting of alkyl groups; m is an integer between 0 and 2.

405. R 7 The compound or salt thereof according to claim 403 or 404, wherein is hydrogen.

406. (i) The compound is VIA or a salt thereof, and m is 0; or (ii) The compound or a salt thereof according to any one of claims 403 to 405, where VIB or a salt thereof, and r is 0.

407. X is NR 8 The compound or salt thereof according to any one of claims 403 to 406.

408. R 8 The compound or salt thereof according to claim 407, wherein the compound is hydrogen.

409. X 2 is CH or CR 10 The compound or salt thereof according to any one of claims 403 to 408.

410. R 10 However, C 1 ~C 6 Alkyl, 0-3 R 13 C having substituents 6 Ariel, C 1 ~C 6 Alkoxy, and C 2 ~C 9 A compound or salt thereof according to any one of claims 403 to 409, which is a member independently selected from the group consisting of alkoxyalkyls.

411. 2 R 10 The bases come together to form 0 to 3 R 13 substituted condensed C 6 A compound or salt thereof according to any one of claims 403 to 410, which forms an aryl ring.

412. R 1 is hydroxyl or C 1 ~C 6 A compound or salt thereof according to any one of claims 403 to 411, which is an alkoxy.

413. A compound or salt thereof according to any one of claims 403 to 412, wherein p is 0.

414. A compound or salt thereof according to any one of claims 403 to 413, wherein q is 1.

415. Each R 2a or R 2b A compound or salt thereof according to any one of claims 403 to 414, wherein the compound is hydrogen.

416. A compound or salt thereof according to any one of claims 403 to 415, wherein L is methylene.

417. A pharmaceutical composition comprising a compound according to any one of claims 403 to 416 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

418. MASP-2 inhibitory compounds for therapeutic use in the treatment of MASP-2-related diseases or disorders, comprising the following formula or a salt thereof: During the ceremony, A 1 -(C=NH)-, -(C=NOR a )-,-[C=NO(C=O)R a ]-,-[C=N[O(C=O)ZR b The member is selected from the group consisting of ]}-, condensed 5-membered or 6-membered heterocyclyls, and condensed 5-membered or 6-membered heteroaryls; A 1 If Y is -(C=NH)-, 1 wa-NH 2 -NH(C=O)R a , and -NH(C=O)ZR b Selected from the group consisting of; A 1 -(C=NOR a )-,-[C=NO(C=O)R a ]-, or -{C=N[O(C=O)ZR b ]}- If Y 1 wa-NH 2 and; A 1 If Y is a condensed heterocyclyl or heteroaryl, 1 wa-NH 2 Or it is a halo, A 1 m further R 1 It is substituted with the base; Each R a and R b C 1 ~C 6 Alkyl, C 3 ~C 10 Cycloalkyl, C 6 ~C 10 Aryl, and C 7 ~C 12 Selected from the group consisting of arylalkyl groups; R a C 1 ~C 6 Alkyl, hydroxyl, hydroxyl (C 1 ~C 6 Alkyl), C 1 ~C 6 Alkoxy, C 2 ~C 9 Alkoxyalkyl, amino, C 1 ~C 6 It has m substituents selected from the group consisting of alkylaminos and halos; or alternatively, R a and R b They came together, C 1 ~C 6 Alkyl, hydroxyl, C 1 ~C 6 A heterocyclyl ring having m substituents selected from the group consisting of alkoxys and halos is formed; Each Z is independently selected from the group consisting of O and S; A 2 C 3 ~C 6 Heteroaryl and C 2 ~C 6 A member selected from the group consisting of alkyl groups; A 2 C 3 ~C 6 If it is a heteroaryl, Y 2 wa-NH 2 ,-CH 2 NH 2 , chloro, -(C=NH)NH 2 -(C=NH)NH(C=O)R a -(C=NH)NH(C=O)ZR b ,-(C=NOR a )NH 2 -[C=NO(C=O)R a ]NH 2 , and -{C=N[O(C=O)ZR b ]}NH 2 Selected from the group consisting of; A 2 m further R 1 It is substituted with the base; A 2 C 2 ~C 6 If it is alkyl, Y 2 is -NH(C=NH)NH 2 -NH(C=NH)NH(C=O)R a , and -NH(C=NH)NH(C=O)ZR b Selected from the group consisting of; Each R 1 C 1 ~C 6 Alkyl, hydroxyl, C 1 ~C 6 Alkoxy, amino, C 1 ~C 6 A member independently selected from the group consisting of alkylamino and halo; Each m and n is an independently selected integer between 0 and 3; L is -(O) p -(C(R 2a )(R 2b )) q -and, Each R 2a or R 2b is a member independently selected from the group consisting of hydrogen and fluoro; p is an integer between 0 and 1; q is an integer between 1 and 2; R 3 is hydrogen, C 1 ~C 6 Alkyl and carboxyl (C 1 ~C 6 A member selected from the group consisting of alkyl groups; Each R 11 C 1 ~C 6 Alkyl, hydroxyl, C 1 ~C 6 Alkoxy, amino, C 1 ~C 6 alkylamino, halo, and (R 14 )(R 14 A member independently selected from the group consisting of )N(CO)-; or alternatively, two R 11 The two elements come together in a condensation C 6 Aryl ring, heteroaryl ring, or C 5 ~C 7 Cycloalkyl ring (0 to 3 R 13 Forms (having substituents); r is an integer between 0 and 4; Each Z is O and NR 8 A member independently selected from the group consisting of; Each R 8 is hydrogen and C 1 ~C 6 A member independently selected from the group consisting of alkyl groups; Each R 12 is hydrogen, C 1 ~C 6 Alkyl, and C 7 ~C 14 Arylalkyl (0-3 R 13 A member independently selected from the group consisting of (having substituents); Each R 13 C 1 ~C 6 Alkyl, hydroxyl, hydroxyl (C 1 ~C 6 Alkyl), C 1 ~C 6 Alkoxy, C 2 ~C 9 Alkoxyalkyl, amino, C 1 ~C 6 A member independently selected from the group consisting of alkylamino and halo; or alternatively, two R 13 The two elements combine to form a condensed C 6 Aryl ring, heteroaryl ring, or C 5 ~C 7 Forming a cycloalkyl ring; Each R 14 is hydrogen, C 1 ~C 6 Alkyl, C 3 ~C 7 Cycloalkyl, C 4 ~C 8 Cycloalkylalkyl, C 7 ~C 14 Arylalkyl and heteroaryl(C) 1 ~C 6 A member independently selected from the group consisting of alkyls; or alternatively, two R 13 The groups combine to form a condensed heterocyclyl ring.

419. The compound according to claim 418, which is formula (VIIC) or a salt thereof: In the formula, each R 7 These are hydrogen, hydroxyl, and C 1 ~C 6 It is a member selected from the group consisting of alkyl groups.

420. R 7 The compound or salt thereof according to claim 418 or 419, wherein is hydrogen.

421. R 3 The compound or salt thereof according to any one of claims 418 to 420, wherein the compound is a member selected from the group consisting of hydrogen or methyl.

422. R 3 The compound or a salt thereof according to claim 421, wherein is methyl.

423. A compound or salt thereof according to any one of claims 418 to 422, wherein Z is O.

424. R 11 (R 14 )(R 14 A compound or salt thereof according to any one of claims 418 to 423, wherein the compound is N(CO)-.

425. R 11 (R 14 The compound or salt thereof according to claim 424, wherein it is (H)N(CO)-.

426. R 14 C 1 ~C 6 Alkyl, C 3 ~C 7 Cycloalkyl, or C 4 ~C 8 The compound or a salt thereof according to claim 425, which is a cycloalkylalkyl compound.

427. R 12 is hydrogen or C 7 ~C 14 A compound or salt thereof according to any one of claims 418 to 426, wherein the compound is an arylalkyl compound.

428. R 1 is hydroxyl or C 1 ~C 6 A compound or salt thereof according to any one of claims 418 to 427, which is an alkoxy.

429. A compound or salt thereof according to any one of claims 418 to 428, wherein p is 0.

430. A compound or salt thereof according to any one of claims 418 to 429, wherein q is 1.

431. Each R 2a or R 2b A compound or salt thereof according to any one of claims 418 to 430, wherein the compound is hydrogen.

432. A compound or salt thereof according to any one of claims 418 to 431, wherein L is methylene.

433. A pharmaceutical composition comprising a compound according to any one of claims 418 to 432 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

434. A small molecule compound exhibiting MASP-2 inhibitory activity for use in therapies for the treatment of MASP-2-related diseases or disorders, wherein the compound interacts with a certain binding site, and the interaction is one or more of (a) to (e): (a) Interacts with one or more amino acid residues in the binding site of MASP-2 (SEQ ID NO: 1) via H-bonds; (b) Interacting at the binding site of SEQ ID NO: 1 by ionic interaction, electrostatic interaction, or hydrogen bonding; (c) Water molecules interact with the binding site of SEQ ID NO: 1; (d) Interacts with one or more amino acid residues in the binding site of SEQ ID NO: 1 via π-π interactions; and / or (e) Interacts with one or more amino acid residues in the binding site of SEQ ID NO: 1 via van der Waals contact; where the compound is not an endogenous MASP-2 ligand.

435. The compound according to claim 434, exhibiting one, two, three, four, or five of the interactions (a) to (e).

436. The compound according to claim 434 or 435, which is bound to one or more amino acid residues in the binding site of SEQ ID NO: 1 by 1 to 10 H bonds.

437. The compound according to any one of claims 434 to 436, which is bound at the binding site of SEQ ID NO: 1 by a water molecule.

438. The compound according to any one of claims 434 to 437, wherein 1 to 20 water molecules bind at the binding site of SEQ ID NO:

1.

439. The compound according to any one of claims 434 to 438, which is bound at the binding site of SEQ ID NO: 1 by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 water molecules.

440. The compound according to any one of claims 434 to 439, which interacts with one or more amino acid residues in the binding site of SEQ ID NO: 1 by van der Waals contact.

441. A compound according to any one of claims 434 to 440, having a molecular weight of approximately 300 g / mol to approximately 600 g / mol.

442. A method for identifying small molecules capable of inhibiting MASP-2, (a) A step of screening a small molecule library using in silico docking for candidate small molecules selectively identified for their ability to target and bind to MASP-2 surface residues at the binding site of the MASP-2 model; and (b) Testing / evaluating the candidate agents identified in step (a) through one or more in vitro assays for their ability to target and bind to MASP-2 surface residues, thereby identifying small molecules capable of inhibiting MASP-2. Methods that include...

443. The method according to claim 442, wherein the candidate small molecule comprises a unique chemical scaffold identified in step (b) and is optimized with respect to its ability to inhibit MASP-2.

444. The method according to claim 442 or 443, wherein the binding site is identified using the MASP-2 model.

445. The method according to any one of claims 442 to 444, wherein the MASP-2 protein model is computationally derived from crystallographic data.

446. The method according to claim 445, wherein the MASP-2 protein model is confirmed by RMSD (mean squared deviation) and superposition for each crystal structure.

447. The method according to any one of claims 442 to 446, wherein in silico docking includes computational docking of a small molecule onto surface-exposed residues of the binding site of the MASP-2 model.

448. The method according to any one of claims 442 to 447, wherein docked ligand orientations are sampled, scored, and binned to specify a distance cutoff value for matching ligand atoms to MASP-2 surface-exposed atoms.

449. (a) A step of screening a small molecule library using in silico docking for candidate small molecules selectively identified for their ability to target and bind to MASP-2 surface residues at the binding site of the MASP-2 model; and (b) Testing / evaluating the candidate agents identified in step (a) through one or more in vitro assays for their ability to target and bind to MASP-2 surface residues, thereby identifying small molecules capable of inhibiting MASP-2. A compound that is a candidate small molecule agent identified by a method including the following.

450. The compound according to claim 449, having a molecular weight of approximately 300 g / mol to approximately 600 g / mol.

451. The compound according to claim 449 or 450, wherein the Ki for MASP-2 is lower than that for thrombin.

452. A method for treating a MASP-2-related disease or disorder in a subject in need, comprising the step of administering to the subject an effective amount of a small molecule MASP-2 inhibitor that binds to the catalytic substrate-binding domain of MASP-2.

453. A method for treating a MASP-2-related disease or disorder in a subject in need, comprising the step of administering to the subject an effective amount of a small molecule MASP-2 inhibitor that binds to a binding site comprising the S1, S2, and S3 regions of MASP-2, and optionally further comprising the S4 and RM regions.

454. A method for treating MASP-2-related diseases or disorders in subjects requiring such treatment, comprising the amino acids ALA 468, ALA 469, HIS 483, ASP 526, ALA 527, GLY 528, PHE 529, LEU 575, TYR 602, PRO 606, TYR 607, PRO 608, SER 611, ASP 627, SER 628, CYS 629, ARG 630, GLY 631, ASP 632, SER 633, GLY 634, GLY 635, VAL 653, SER 654, TRP 655, GLY 656, SER 657, MET 658, ASN 659, CYS 660, GLU 662, GLN 665, TYR 666, GLY 667, VAL 668, and TYR 669, amino acids ALA 468, ALA 469, HIS 483, ASP 526, ALA 527, GLY 528, PHE 529, LEU 575, TYR 602, PRO 606, TYR 607, PRO 608, SER 611, ASP 627, SER 628, CYS 629, ARG 630, GLY 631, ASP 632, SER 633, GLY 634, GLY 635, VAL 653, SER 654, TRP 655, GLY 656, SER 657, MET 658, ASN 659, CYS 660, GLU 662, GLN 665, TYR 666, GLY 667, VAL A method comprising the step of administering to a subject an effective amount of a small molecule MASP-2 inhibitor that binds to a binding site comprising any one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelfth, thirteen, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twenty-one, twenty-one, twenty-two, twenty-two, twenty-threeteenth, twenty-fiveth, twenty-sixth, twenty-seventh, twenty-eighth, twenty-nineth, thirty-one, thirty-one, thirty-two, thirty-two, thirty-two, thirty-threeteenth, thirty-fiveth, thirty-fiveth, thirty-one or thirty-sixth subset of 668 and / or TYR 669.

455. A method for treating a MASP-2-related disease or disorder in a subject in need, comprising the step of administering to the subject an effective amount of a small molecule MASP-2 inhibitor or a pharmaceutically acceptable composition thereof according to any one of claims 1 to 441.

456. The method according to any one of claims 452 to 455, wherein the compound is administered in an amount sufficient to inhibit MASP-2-dependent complement activation in the subject.

457. The method according to any one of claims 452 to 456, wherein the subject has been diagnosed with a lectin complement-related disorder or condition requiring treatment.

458. The method according to any one of claims 452 to 457, wherein the disease or disorder is thrombotic microangiopathy (TMA), renal condition, inflammatory response resulting from tissue transplantation or organ transplantation, ischemia-reperfusion injury, complications associated with diabetes, cardiovascular disease or cardiovascular disorder, inflammatory gastrointestinal disorder, lung disorder, eye disease or eye disorder, disseminated intravascular coagulation, graft-versus-host disease, venous occlusion, or diffuse alveolar hemorrhage.

459. The method according to any one of claims 452 to 457, wherein the disease or disorder is thrombotic microangiopathy (TMA), thrombotic thrombocytopenic purpura (TTP), refractory TTP, Upshaw-Schulmann syndrome (USS), hemolytic uremic syndrome (HUS), atypical hemolytic uremic syndrome (aHUS), factor H-independent atypical hemolytic uremic syndrome, aHUS secondary to infection, plasma therapy-resistant aHUS, TMA secondary to cancer, TMA secondary to chemotherapy, TMA secondary to transplantation, or TMA associated with hematopoietic stem cell transplantation.

460. The method according to any one of claims 452 to 457, wherein the disease or disorder is graft-versus-host disease.

461. The method according to any one of claims 452 to 457, wherein the disease or disorder is diffuse alveolar hemorrhage (DAH).

462. The method according to any one of claims 452 to 457, wherein the disease or disorder is venous occlusion (VOD).

463. The method according to any one of claims 452 to 457, wherein the disease or disorder is a renal condition.

464. The method according to claim 463, wherein the renal condition is mesangial proliferative glomerulonephritis, membranous glomerulonephritis, membranoproliferative glomerulonephritis (mesangial capillary glomerulonephritis), acute post-infectious glomerulonephritis (post-streptococcal glomerulonephritis), C3 glomerulopathy, cryoglobulinemia glomerulonephritis, microimmune necrotizing crescentic glomerulonephritis, lupus nephritis, Henoch-Schönlein purpura nephritis, or IgA nephropathy.

465. The method according to any one of claims 452 to 457, wherein the disease or disorder is renal fibrosis and / or renal proteinuria.

466. The method according to any one of claims 452 to 457, wherein the disease or disorder is an inflammatory response resulting from tissue transplantation or parenchymal organ transplantation.

467. The method according to any one of claims 452 to 457, wherein the disease or disorder is ischemia-reperfusion injury (I / R).

468. The method according to any one of claims 452 to 457, wherein the disease or disorder is a complication associated with non-obese diabetes mellitus and / or a complication associated with type 1 or type 2 (adult-onset) diabetes mellitus.

469. The method according to any one of claims 452 to 457, wherein the disease or disorder is a cardiovascular disease or cardiovascular disorder.

470. The method according to any one of claims 452 to 457, wherein the disease or disorder is an inflammatory bowel disorder.

471. The method according to any one of claims 452 to 457, wherein the disease or disorder is a lung disorder.

472. The method according to any one of claims 452 to 457, wherein the disease or disorder is an extracorporeal exposure-induced inflammatory response, and the method includes the step of treating a subject undergoing an extracorporeal circulation procedure.

473. The method according to any one of claims 452 to 457, wherein the disease or disorder is inflammatory or non-inflammatory arthritis, or other musculoskeletal disorder.

474. The method according to any one of claims 452 to 457, wherein the disease or disorder is a skin disorder.

475. The method according to any one of claims 452 to 457, wherein the disease or disorder is a disorder or injury of the peripheral nervous system (PNS) and / or the central nervous system (CNS).

476. The method according to any one of claims 452 to 457, wherein the disease or disorder is sepsis or a condition resulting from sepsis.

477. The method according to any one of claims 452 to 457, wherein the disease or disorder is a urogenital disorder.

478. The method according to any one of claims 452 to 457, wherein the disease or disorder is an inflammatory response in a subject being treated with a chemotherapeutic agent and / or radiotherapy.

479. The method according to any one of claims 452 to 457, wherein the disease or disorder is angiogenesis-dependent cancer.

480. The method according to any one of claims 452 to 457, wherein the disease or disorder is an angiogenesis-dependent benign tumor.

481. The method according to any one of claims 452 to 457, wherein the disease or disorder is an endocrine disorder.

482. The method according to any one of claims 452 to 457, wherein the disease or disorder is an eye disease or eye disorder.

483. The method according to any one of claims 452 to 457, wherein the disease or disorder is an intraocular neovascular disease or an intraocular neovascular state.

484. The method according to any one of claims 452 to 457, wherein the disease or disorder is disseminated intravascular coagulation (DIC) or another complement-mediated coagulation disorder.

485. The method according to any one of claims 452 to 457, wherein the disease or disorder is acute radiation syndrome, dense deposit disease, Degos disease, fulminant antiphospholipid syndrome (CAPS), Behçet's disease, cryoglobulinemia, paroxysmal nocturnal hemoglobinuria ("PNH"), or cold agglutinin disease.

486. The method according to any one of claims 452 to 457, wherein the disease or disorder is atypical hemolytic uremic syndrome (aHUS).

487. The method according to any one of claims 452 to 457, wherein the disease or disorder is hematopoietic stem cell transplant-related TMA.

488. The method according to any one of claims 452 to 457, wherein the disease or disorder is immunoglobulin A nephropathy (IgAN).

489. The method according to any one of claims 452 to 457, wherein the disease or disorder is lupus nephritis (LN).

Images